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AEC – 3-Amino-9ehtylcarbazole
ALPS- Autoimmune Lymphoprolife-
rative Syndrome
APC- Antigen Presenting Cell
BM – Bone Marrow
BrDU - 5-bromo-2’-deoxyuridine
BSA – Bovine Albumin Serum
CBL – Casital B-lineage Lymphoma
CD – Cluster of Differentiation
CHO  - Chinese Hamster Ovary
CX3CL1 - Chemokine (C-X3-C 
motif) ligand 1
DNAM-1 – DNAX accessory mole-
cule 1
EDTA – Ethylenediaminetetraacetic 
acid 
ELISA – Enzyme-Linked Immuno-
Sorbent Assay
FACS – Fluorescence-Activated 
Cell Sorting 
FBS – Fetal Bovine Serum
G418 – Geneticin
Grb2 – Growth factor receptor-
bound protein 2
HBS – HEPES Buffered Saline
HIER – Heat Induced Epitope 
Retrieval
HSC – Hematopoietic stem cell
ICAM1 – Inter-Cellular Adhesion 
Molecule 1
IF - ImmunoFluorescence
IFN-γ  - Interferon gamma
IHC – Immunohistochemistry
IL-2 – Interleukin  2
IL-6 – Interleukin 6
IL-10 – Interleukin 10
IL-12 – Interleukin 12
IL-15 – Interleukin 15
IP-10 - Interferon gamma-induced 
protein 10
iNK – Immature Natural Killer Cell
ITAM – Immunoreceptor Tyrosine-
based Activation Motif
JAK – Janus Kinase
KIR – Killer-cell Immunoglobulin-
like Receptor
LIN – Lineage
LPR - Lymphoproliferation sponta-
neous mutation
Ly49 – Killer cell lectin-like recep-
tor subfamily 49
MAPKs – Mitogen Activated Pro-
tein Kinases
MHC – Major Histocompatibility 
Complex
MULT-1 - Murine UL16-binding 
protein-like transcript
MRL – Murphy Roths Large mouse
MS – Multiple Sclerosis
NK – Natural Killer Cell
NK1.1 – NK cell associated marker
NKG2D - Natural Killer Group 2D 
Receptor
NKP – Natural Killer Precursor
O/N – Overnight
PBMC – Peripheral Blood Mono-
nuclear Cell
PBS – Phosphate Buffered Saline
PFA - Paraformaldehyde
PI – Propidium Iodide
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PI3K – Phosphoinositide 3-kinase
PMA - Phorbol 12-myristate 
13-acetate
RA – Rheumatoid Arthritis
Rae – retinoic acid early inducible 
gene 1
RAG – Recombination Activating 
Gene
RANTES - Regulated on Activa-
tion, Normal T cell Expressed and 
Secreted cytokine
RMA/S - Rauscher murine leukemia 
virus-induced tumors cell line
RPMI – Roswell Park Memorial 
Institute medium
RT – Room Temperature
S2 – Drosophila Schneider 2 Cells
SLE – Systemic Lupus Erythemato-
sus
STAT5  - Signal Transducer and 
Activator of Transcription 5 protein
T1D – Type 1 Diabetes
TCR – T Cell Receptor
Th-1 – T-helper cell type 1
Th-2 – T-helper cell type 2
TNF-α – Tumor Necrosis Factor 
Alpha
WT – Wild type
YAC-1 - T cell lymphoma induced 
by inoculation of the Moloney leuke-
mia virus (MLV) into a newborn A/
Sn mouse
Summary

17
 Natural killer (NK) cells are large granular lymphocytes that play an important part as 
a link between the innate and adaptive immune systems.  Various autoimmune diseases are cor-
related with alterations in the activity of NK cells; nonetheless, their role in the pathogenesis of 
systemic	lupus	erythematosus	(SLE),	a	complex	multi-factorial	disease,	has	not	been	extensively	
studied.  One of the most important activating NK cell receptors is NKG2D, which is able to sig-
nal	via	the	p85	subunit	(either	the	α	or	β	subunit)	of	the	PI3K	(phosphatidylinositide	3-kinase)	
enzyme, to which it binds indirectly via the DAP10 adaptor molecule.  It is not known which of 
the	two	p85	subunits	binds	preferentially	to	DAP10,	or	whether	the	p85β	subunit	participates	in	
mediating NKG2D receptor signaling.
	 In	the	first	part	of	this	work,	we	studied	the	role	of	NK	cells	in	murine	models	of	SLE.		
We	show	that	the	MRL/MpJ	mouse	is	a	useful	model	for	this	analysis,	and	that	NK	cells	in	
diseased	mouse	spleen	suffer	from	impaired	differentiation,	which	is	site-specific.		In	addition,	
we	show	that	NK	cells	in	the	kidneys	of	diseased	SLE-like	mice	are	phenotypically	more	mature	
and more active compared to those of healthy mice and in other non-target organs.  We report 
the	expression	of	the	NKG2D	ligands	Rae-1	and	Mult-1	specifically	in	the	glomeruli	of	various	
lupus-prone mouse models.  Expression of these ligands increases concomitantly with disease 
state	and	influences	NK	cell	maturation	and	IFN-γ	production.
	 For	the	second	section	of	the	study,	we	analyzed	the	PI3K	p85β	subunit	function	in	
NK	cells.		We	demonstrate	that	p85β	is	not	involved	in	NK	cell	differentiation,	proliferation,	or	
maturation.		The	p85β-deficient	NK	cell	phenotype	is	more	activated	than	that	of	control	mouse	
NK cells, as seen via cytotoxicity assays and cytokine secretion.  We found that this activated 
phenotype	is	probably	due	to	the	role	of	p85β	in	NKG2D	internalization,	which	is	impaired	in	as	
p85β-deficient	NK	cells.
	 Our	findings	identify	an	undescribed	NK	cell	function	in	SLE	pathogenesis	and	of	the	
p85β	PI3K	subunit	in	the	regulation	of	the	NKG2D	receptor	function.

Resumen
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	 Las	células	“asesinas	naturales”	(NK)	son	linfocitos	que	sirven	como	enlace	entre	el	
sistema	inmune	adaptativo	e	innato.	Alteraciones	en	la	actividad	en	las	células	NK	están	correla-
cionadas	con	enfermedades	autoinmunes,	aunque	el	papel	de	estas	células	en	el	Lupus	Sistémico	
Eritromatoso	(SLE),	una	enfermedad	compleja	y	multifactorial,	aún	sigue	siendo	controvertido.		
Uno	de	los	receptores	de	activación	mas	importantes	en	las	células	NK	es	el	receptor	NKG2D.		
NKG2D	se	une	a	la	molécula	adaptadora	DAP10,	y	señaliza	a	través	de	la	subunidad	p85	del	
enzima	PI3K.			Aún	no	se	sabe	cual	de	las	dos	subunidades	de	p85	se	une	preferiblemente	a	la	
molécula	adaptadora	DAP10,	ni	si	la	subunidad	p85β	tiene	un	papel	en	la	señalización	mediada	
por el receptor NKG2D.
	 En	la	primera	parte	de	este	trabajo,	hemos	estudiado	el	papel	de	las	células	NK	en	
modelos	murinos	de	SLE.		Demostramos	que	el	modelo	MRL/MpJ	es	un	modelo	válido	para	
el	estudio	de	células	NK	en	SLE,	y	que	las	células	NK	en	el	bazo	de	ratones	enfermos	tienen	
defectos	en	diferenciación.		Demostramos	también	que	células	NK	en	los	riñones	de	ratones	
enfermos	con	SLE	son	fenotipicamente	más	maduras	y	más	activas	comparadas	con	las	células	
NK	de	ratones	sanos,	y	con	las	células	NK	presentes	en	órganos	no	afectados	por	la	enfermedad.		
Además,	reportamos	la	expresión	de	los	ligandos	de	NKG2D	Rae-1	y	Mult-1	específicamente	en	
los	glomérulos	de	varios	ratones	con	susceptibilidad	genética	a	desarrollar	SLE.		La	expresión	
de estos ligandos aumenta con la progresión de la enfermedad, y que la expresión de estos ligan-
dos	influye	en	la	maduración	y	producción	de	IFN-γ	por	parte	de	células	NK.	
	 En	la	segunda	parte	de	este	trabajo	hemos	estudiado	el	papel	de	la	subunidad	p85β	
en	células	NK.	Demostramos	que	la	subunidad	p85β	no	está	involucrada	en	la	diferenciación,	
proliferación,	o	maduración	de	células	NK.		Sin	embargo,	mostramos	cómo	las	células	NK	de	
ratones	deficientes	de	p85β	tienen	un	fenotipo	mas	activado,	como	se	demuenstra	mediante	
ensayos	de	citotoxicidad	y	secreción	de	citoquinas.		Este	fenotipo	más	activo	podría	deberse	al	
papel	que	p85β	juega	en	la	internalización	de	NKG2D,	dado	que	las	células	NK	deficientes	en	
p85β	tienen	defectos	en	la	internalización	de	dicho	receptor.	
	 Estos	resultados	indican	un	papel	nuevo	para	las	células	NK	en	la	patogénesis	de	SLE	y	
de	la	subunidad	p85β	de	PI3K	en	la	regulación	de	las	funciones	del	receptor	NKG2D.
Introduction
If I have seen further it is by standing on the shoulder of giants
Sir Isaac Newton
The	last	thing	one	discovers	in	composing	a	work	is	what	to	put	first
	Blaise	Pascal,	Pensées
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Part 1 – Natural Killer Cells – Functions and development
Natural Killer Cell functions and its receptors
 Natural killer (NK) cells are large granular lymphocytes that constitute an essential ele-
ment of the innate immune system, being after T and B cells, the third major lineage of lympho-
cytes	[1].	NK	cells	were	first	characterized	for	their	capacity	to	kill	tumor	targets	without	prior	
sensitization [2, 3].  NK cells are in fact well known for their capacity to lyse susceptible target 
cells via the exocytosis of perforin and granzyme granules, which are capable of inducing apop-
tosis in, targeted cells [4].  NK cells are also known to be rapid producers of various cytokines 
and	chemokines	such	as	IFN-γ,	TNF-α,	RANTES,	MIP-1α/β	which	are	capable	of	amplifying	and	
recruiting	an	inflammatory	response	via	various	mechanisms	[5,	6].					
 Their main distinction from T and B cells is that NK cells do not use the recombination-
activating	gene	enzymes	(RAG)	for	the	rearrangement	of	their	receptor	genes	and	they	do	not	pos-
sess	a	unique	antigen	recognition	receptor	[7,	8].	This	NK	cell	specific	characteristic	is	determined	
by their capacity to interact with virtually all nucleated cells, via a family of inhibitory receptors, 
either	the	Ly49	family	in	mice,	or	the	killer	cell	immunoglobulin-like	receptor	(KIR)	family	in	
humans [9].  These receptors are capable of ascertaining if the cells with whom the NK cells inter-
act	express	the	correct	self-MHC	profile.		The	lack	of	a	correct	MHC-profile,	usually	via	the	lack	
of MHC class I molecules, does not allow for the binding of these inhibitory NK cell receptors, 
and thus allows for subsequent NK cell activation and lysis of the target cell.  This was what was 
referred	to	as	the	“missing-self”	hypothesis,	and	was	specifically	noted	in	MHC-I	class	deficient	
tumor cell lines [10]. 
 Substantial evidence is now had that NK cells do not only possess inhibitory, but also 
activatory receptors (Table I.1).  Activatory receptors in NK cells include a myriad of different 
subsets,	 including	 the	CD49/NKG2C	 complex,	NKp46	 and	NKG2D	 (found	 in	 both	mice	 and	
humans),	Ly49	subsets	(in	mice),	and	the	KIR	S	family	in	humans	[11].		These	activatory	recep-
tors	are	capable	of	recognizing	both	foreign	and	self-proteins.		Indeed,	some,	such	as	Ly49H	are	
capable of recognizing the cytomegaloviral MHC Class I-related molecule, others such as NKp46 
bind viral haemagglutinins, and other receptors, such as NKG2D, bind self-molecules which are 
upregulated	on	the	cell	membranes	of	“stressed”	or	virally	infected	cells	[12-14].	NKG2D	activa-
tion correlates with that of NK cells, leading to the lysis of infected, stressed or cancer cells, both 
in	vivo	and	in	vitro	[15,	16].		NKG2D	is	activated	by	NKG2D	ligands,	a	“stress-induced”	family	
of	MHC-I-like	proteins.		Seven	ligands	are	reported	in	humans	(MICA,	MICB,	ULBP1-ULB4,	
RAET1G)	and	mice	(Rae1α/β/γ/ε/δ,	MULT-1,	H60).	This	has	led	to	a	revised	theory	on	the	“miss-
ing	self”	hypothesis,	in	which	an	NK’s	activatory/quiescent	state	is	struck	by	a	balance	of	its
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activatory and inhibitory receptors on its cell surface [17].
Table I.1 – List of the main adhesion, activating and inhibitory receptors of 
murine NK cells
Development of Natural Killer Cells
 NK cells are known to develop primarily in the bone marrow (BM), and unlike T cells, do 
not require the thymus for their development, since various studies have reported normal numbers 
of NK cells in athymic nude mice [2, 3, 18].   NK cells, as is the case with all cells in the heam-
atopoietic system, are derived from BM heamatopoietic stem cells (HSC).  Via a continuous
Receptor Class ,o-./0daptor Ligand 
Adhesion	  Receptor 
CD2	  (LFA-­‐2) IgSF Proline-­‐rich	  domain CD48,	  CD58 
CD11a	  (LFA-­‐1) IgSF Src	  family	  kinases,	  
PI3K 
CD54	  (ICAM-­‐1),	  
CD107	  (ICAM-­‐2) 
CD11b	  (MAC-­‐1) IgSF ? CD54	  (ICAM-­‐1) 
CD43	   IgSF ? E-­‐SelecNn	  (?) 
CD49b	  (DX5) IgSF ? Collagen	  (?) 
AcNQaNng	  Receptors 
CD69 C-­‐lecNn ? ? 
CD122	  (IL-­‐2Rβ) Cytokine	  Receptor JAK1,	  3;	  	  STAT5 IL-­‐2,	  IL-­‐15 
NKG2D C-­‐LecNn YINM/DAP10,	  PI3K Rae1,	  Mult-­‐1,	  H60 
Ly49	  D,	  H,	  P C-­‐LecNn ITAM/DAP12 H-­‐2	  class	  I,	  MCMV 
DNAM-­‐1 IgSF ? CD112 
NK1.1 C-­‐LecNn FCεRIγ ? 
NKp46 IgSF ? Viral	  HA,	  HSPG 
Inhibitory	  receptors 
NKG2A C-­‐lecNn ITIM/SHP-­‐1 Qa1b 
CD244 SLAM TXYXXV-­‐I/SAP CD48 
Ly49	  A-­‐C,	  E-­‐G,	  I-­‐O C-­‐lecNn ITIM/SHP-­‐1,	  -­‐2 H-­‐2	  class	  I 
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and sequential loss of pluripotency, HSCs differentiate into what are known as Natural Killer 
cell precursors (NKP).  NKPs have been characterized in the BM and fetal thymus of mice with 
a	Lin-CD122+NK1.1-DX5-	phenotype[1,	19,	20].	CD122	is	a	70-75	kD	IL-2	receptor	β	chain	also	
known	as	IL-2Rβ,	which	is	also	shared	by	the	IL-15	receptor[1,	21].		Its	expression	is	crucial	for	
the	further	development	of	NKPs,	as	it	allows	NKPs	to	respond	to	IL-15	stimulation[22].		IL-15	
has been described as the main player in NK cell development in the bone marrow, as studies us-
ing	IL-15	knockout	mice	are	almost	completely	devoid	of	NK	cells	[23-25].		Furthermore,	NKP	
cells	stimulated	with	IL-15	are	capable	of	proliferating	and	differentiating	into	mature	NK	cells	
with	both	cytotoxic	and	cytokine	secretion	capacities	[1,	20].		Nonetheless,	IL-15	is	not	the	be-all	
and	end-all	of	NK	cell	development.	Indeed,	even	though	IL-15	deficient	mice	were	almost	devoid	
of NK cells, the mere presence of residual NK cells, and the fact that these show some degree of 
maturation indicate that more cytokines and or factors play a role in NK cell arisal. [26-28]. Once 
formed, NKPs must progress into fully mature phenotypic and functional NK cells (mNK). This 
occurs via the continuous process of NKP maturation into immature NK cells (iNK). iNK cells are 
characterized via several markers which can distinguish differentiating NK cells.  iNK cells still 
lack	both	the	complete	and	functional	attributes	of	mNK	cells,	and	are	defined	via	the	progressive	
acquisition of NK cell markers such as CD122, NK1.1, DX5, NKG2D, CD27, CD43, and CD11b 
[29] (Figure I.1).
NK cell trafficking
 It was originally postulated that NKPs would arise in the BM, differentiate, and then 
start recirculating in the body.  Indeed, evidence supports the idea that the BM is the primary 
site of NKP generation, seeing as how BM ablation drastically reduces both the number and 
functional capacities of NK cells [30].  However, various groups have also shown the presence 
of	NKP	and	iNK	cells	in	both	mouse	and	human	lymph	nodes	(LN),	thymus,	spleen,	and	liver	
[31-34] .  The presence of NKP and iNK cells outside of the BM raises the question on whether 
or not the BM is only necessary in the initial steps of NK cell differentiation, which would then 
terminate elsewhere [1, 30].   Indeed, it is still not known if these NKP and iNK cells found 
outside of the BM proceed directly from the BM itself, or if they are distinct NK cell lineages. 
	 Regardless	 of	 their	 origin,	 it	 has	 been	 postulated	 that	 NK	 cells	 which	 have	 egressed	
from the BM, recirculate and progress with their maturation in the periphery [30].  Non-iNK 
–NKP cells found in the periphery are usually subdivided into yet another three stages of mat-
uration, which correlate with the gradual acquisition of effector functions.  These stages have 
been	defined	by	the	acquisition	of	the	expression	of	CD11b	and	CD27,	in	the	following	manner:	
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Figure I.1 – Phenotypic and functional acquisition of NK developmental markers
NK cells have been traditionally viewed as following a linear pathway from haematopoietic stem cells (HSCs) in the 
bone marrow which then differentiate and fully mature in the periphery.  NK-cell precursors (NKPs) lack all typical NK-
cell	markers	but	are	characterized	by	the	expression	of	the	IL-2	receptor	β	(CD122).	These	then	give	rise	to	NK	cells	via	
the sequential acquisition of developmental markers, such as the natural-killer group 2, member D receptor (NKG2D) 
and the NK-cell associated marker (NK1.1).  It is thought that NK cell education via MHC-I class molecules occurs in 
the	bone	marrow,	and	that	more-mature	NK	cells	then	leave	and	fully	differentiate	in	peripheral	organs.		(modified	Di	
Santo	et.	al,	2007,	Nature	Reviews)
CD11bLowCD27High (the most immature), CD11bHighCD27High (intermediate maturation), and 
CD11bHighCD27Low (the most mature) [29, 35, 36].  (Figure I.1).
 The proportion of these three subsets varies greatly between tissues, and the main tis-
sues	 which	 have	 been	 studied	 in	 detail,	 have	mainly	 been	 BM,	 LN,	 spleen,	 liver,	 blood	 and	
lungs [37].  Within these tissues, immature CD11bLowCD27High	are	predominantly	 found	 in	LN	
and BM, while the more mature CD11bHighCD27High and CD11bHighCD27Low are usually found
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in the liver spleen and lung [35, 38].  As is the case with the mechanisms behind iNK 
and NKP cells, it is still not known if CD11bLowCD27High	 and/or	 CD11bHighCD27High ar-
rive in these peripheral tissues directly from the BM and then mature directly in situ, or 
if the they directly derive from iNK cells  (Figure I.2).  Nonetheless, it is known that 
splenic NK cells are capable of recirculating back into the BM, and could thus possi-
bly be a part of the small, yet present mNK cell subsets which are found in BM (Figure I.3).
 The cytokines involved in the maturation of NK cells in vivo have still not been 
clearly	 identified,	 even	 though	 the	 importance	 of	 cytokines	 such	 as	 IL-12,	 IL-18,	 and	 IL-21	
in vitro in generating unique mature NK cell phenotypes has already been established [39].
Figure I.2 – CD11b and CD27 NK cell subset circulation
Non-INK – NKP cells are usually subdivided into three stages of maturation which correspond to the acquisition of the 
CD11b and CD27 markers.  NK cells mature from the CD11bLowCD27High  to the CD11bHighCD27High and then onto the 
CD11bHighCD27Low stage. It is thought that any of these NK cell subtypes can freely move from the bone marrow to any 
organ	via	the	blood	stream,	and	finish	their	maturation	in	situ.	(modified	Grégoire	et.al,	2007,	Immunological	Reviews)
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Figure I.3 – NK cell organ recirculation
Generation and recirculation of NKP, iNK and mature NK cell subtypes.  NKP cells are thought to generate in the bone 
marrow, but both NKP, iNK and NK developmental intermediates have been found in other organs, such as liver and 
spleen.		Certain	NK	cell	specific	subsets	seem	to	reside	in	specific	organs,	such	as	mature	CD11bHighCD27Low mature-
NK cells in the lung and immature CD11bLowCD27High NK cells in the spleen, but whether these intermediates actually 
complete	their	differentiation	in	situ	or	elsewhere	is	unknown.	(modified	Di	Santo,	2006,	Annu.	Rev.	Immunol.)
NK cell variations in organs
 Interestingly, the frequency of NK cells in lymphocytes in mice is higher in the non-
lymphoid organs such as the lung and liver compared to lymphoid organs, and the same tendency 
seems to occur in human non-lymhoid tissues [30, 40, 41].  The function and role of tissue-
resident NK cells in different organs has been seen to vary greatly between organs.  For example, 
liver-resident	NK	cells	 have	 been	 seen	 to	 play	 both	 a	 pro-inflammatory	 and	 anti-fibrotic	 role.	
Studies have reported how hepatic NK cells during viral infection have a higher cytotoxic phe-
notype, and produce higher levels of perforin and granzymes [42, 43].  On the other hand, liver
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NK	cells	have	also	play	an	anti-fibrotic	role,	via	their	ability	to	deplete	hepatic	stellate	cells,	which	
are	responsible	for	pro-fibrotic	formation	in	the	liver	[44].		NK	cells	seem	to	exhibit	the	same	ja-
nus-face	also	in	mucosal	tissues	and	skin.		While	lung-specific	viral	infections	increase	the	flow	of	
NK	cells	which	produce	large	levels	of	TNF-α,	NK	cells	in	the	gut	seem	to	participate	with	other	
gut-associated	lymphoid	tissues	in	controlling	a	tolerogenic	status	to	commensal	flora	[45,	46].	
Part 2 – Natural Killer Cells in autoimmunity
Natural Killer Cells in Autoimmunity
	 Autoimmune	 disorders	 can	 be	 generically	 defined	 by	 an	 immune-mediated	 elimina-
tion	or	debilitation	of	endogenous	cells	and/or	tissue.		Autoimmune	diseases	are	typically	char-
acterized via an inappropriate activation of cells of both the adaptive and innate immune sys-
tem,	which	 result	 in	 either	 specific	or	unspecific	cell	or	organ	damage.	 	Autoimmune	diseases	
can be characterized into various subcategories; 1) an unrecognized ongoing infection in the 
target organ 2) a cross-reaction with an environmental antigen (molecular mimicry) 3) bad cell 
death, with subsequent necrotic and not apoptotic cell death 4) the autoimmune response is a 
result, not a cause, of the disease (immune markers) [47].  Notwithstanding, autoimmune dis-
eases seem to be initiated in a step-wise manner, involving the release of self-antigen from tar-
get organs which in turn prime secondary lymphoid organs which ultimately leads to tissue de-
struction [48] . NK cells are capable of partaking in any of the aforementioned steps, seeing 
as	how	they	can	mediate	initial	target	damage	via	the	lysis	of	cells	expressing	“stress”	self-an-
tigens and also by being active immunomodulators and effector cells in target organs [48-50].
 NK cells, the activating NGK2D receptor, and NKG2D ligands have been implicated in vari-
ous	autoimmune	diseases	such	as	type	1	diabetes	(T1D),	rheumatoid	arthritis	(RA),	and	Crohn’s	dis-
ease	[51-56].		Just	as	NK	cells	seem	to	have	different	functions	depending	on	their	peripheral	localiza-
tion, so do NK cells seem to behave differently in the various autoimmune diseases.  As Perricone et. 
al suggested, there seems to be a great variability within and between autoimmune diseases into when 
NK cells act as either shields against autoimmunity, or swords which enhance it (Figure I.4) [49]. 
	 In	multiple	sclerosis	(MS),	NK	cells	seem	to	behave	as	“shields”,	since	patients	in	remis-
sion	from	MS	seem	to	exhibit	high	percentages	of	Th2	cytokine	secreting	NK	cells	(such	as	IL-5	
and	IL-13)	[57,	58].		In	rheumatoid	arthritis,	NK	cells	are	greatly	present	in	the	inflamed	joints,	
and	 recent	 advances	 have	 shown	 how	 synovium-infiltrating	 NK	 cells	 from	 patients	 produced	
more	IFN-γ	and	were	phenotypically	more	active	compared	to	peripheral	blood	NK	cells	from	
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the same patients [59, 60].  The possible role that NK cells might have in systemic lupus erythe-
matosus	(SLE),	has	not	however	been	discussed	at	length.		
Figure I.4 – Pro- and anti-inflammatory NK cells
Various factors are capable of modulating an NK cells capacity to either regulate or down-regulate the immune re-
sponse.		These	factors,	which	can	encompass	such	distinct	stimuli	such	as	they	cytokine	mileu,	organs,	the	inflamma-
tory/infectious	status,	or	genetic	background.		Pro-inflammatory	NK	cells	can	either	release	cytokines	such	as	IFN-γ	
which activate Th1 type T cells and macrophages, or can directly lyse target tissue cells via the release of perforin and 
granzyme.		NK	cells	can	also	play	an	anti-inflammatory	role	in	by	producing	Th2	type	cytokines	such	as	IL-5,	Il-10	and	
TGF-β.		(modified	Johannson	et.	al,	2005,	TRENDS	in	Immunology)
Systemic Lupus Erythematosus
 SLE	is	a	chronic	autoimmune	disease	that	can	affect	various	organs,	including	the	heart,	
lungs, blood, kidneys and nervous system [61, 62].  The etiology of this disease remains unknown, and 
various	studies	postulate	roles	for	genetic	and/or	environmental	factors	in	its	development	[61].		The	
hallmarks	of	SLE	are	auto-antibody	production	to	a	broad	range	of	self-antigens,	immune	complex	
formation, and self-reactive T and B cells able to produce these auto-antibodies [63-65].  Immune 
complex formation in kidney glomeruli is presumed to be an initiator of lupus nephritis, one of the 
main	causes	of	mortality	and	morbidity	in	human	SLE	and	in	murine	SLE	models	[66].		Once	these	
complexes	appear,	interstitial	infiltrates	of	macrophages,	T	and	B	cells	form,	in	turn	amplifying	the	
local	inflammatory	response	[67,	68].		This	accumulation	of	cell	infiltrates	correlates	with	severity	
of the glomerular lesions, leading in turn to glomerulonephritis and eventual renal failure [69, 70].
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Natural Killer Cells in SLE
	 The	 role	 of	 NK	 and	 of	 NKG2D+	 cells	 in	 the	 development	 of	 SLE	 pathogenesis	 re-
mains	unclear	 and	 is	widely	debated.	 	Recent	 reports	 from	several	 groups	 show	a	 significant-
ly	lower	proportion	and	total	numbers	of	NK	cells	in	SLE	patient	blood	compared	to	controls,	
especially in patients with lupus nephritis [71-73].  This reduction in the total numbers of NK 
cells in the peripheral blood seems to be a common hallmark in various autoimmune diseas-
es,	 such	 as	MS,	RA,	T1D,	 and	 Sjögren	 Syndrome,	 even	 though	 its	 significance	 is	 not	 under-
stood [49, 74, 75]. There also is evidence of reduced cytotoxicity and impaired differentiation 
in	NK	cells	from	SLE	patients	and	from	mouse	SLE	models	such	as	MRL/MpJlpr [71, 76, 77]. 
Other studies showed a larger proportion of CD4+NKG2D+ cells in the peripheral blood mono-
nuclear	 cells	 (PBMC)	 of	 SLE	 patients,	 although	 an	 inverse	 correlation	 is	 reported	 between	
CD4+NKG2D+	cells	and	disease	activity	in	juvenile-onset	SLE	patients	[52,	78].		Higher	levels	
of	 the	NKG2D	MICA	ligand	were	also	found	in	 juvenile-onset	SLE	patient	serum,	suggesting	
NKG2D	ligand	upregulation	in	SLE	pathogenesis	[52].		There	are	nonetheless	few	data	regard-
ing	 the	role	of	NKG2D	and	its	 ligands	 in	SLE	pathogenesis	and	etiology,	or	on	 the	functional	
characterization	of	NK	cells	in	a	SLE	environment,	specifically	in	target	organs	of	this	disease.
Part 3 – The NKG2D receptor and its signaling pathway
NKG2D activating receptor
 One of the main NK cell activating receptors is the NKG2D activating receptor which 
is expressed on most NK, NKT, activated CD8 T cells, and gδ	T	cells	[12,	17,	51].		NKG2D	is	
a highly conserved, non-ITAM (immunoreceptor tyrosine-based activation motif), C-type lec-
tin-like, type II transmembrane glycoprotein which is encoded by a single gene [79]. NKG2D 
in	mice	exists	both	in	a	long	(NKG2D-L)	and	short	(NKG2D-S)	form	which	are	generated	via	
alternative	RNA	 splicing	 [80].	 	The	NKG2D-L	 protein	 associates	with	DAP10,	 a	 trans-mem-
brane signaling subunit, while the NKG2D-S can pair either with DAP10 or DAP12, another 
trans-membrane subunit.  The human trans-membrane unit of NKG2D can only associate with 
DAP10 and not DAP12 (Figure I.5). While it has been seen that the NKG2D-DAP10 signal-
ing pathway plays a crucial role in NKG2D mediated cytotoxicity, the role DAP10 and DAP12 
have	in	NKG2D	mediated	cytokine	production	is	less	clear	[17].		Indeed,	DAP10	deficient	mice	
which only express NKG2D-DAP12 complexes, are capable of cytokine secretion and cytotox-
icity	when	NKG2D	is	crosslinked,	while	in	contrast	DAP12	deficient	mice	which	only	express	
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NKG2D-DAP10  complexes, cytotoxicity but not cytokine production is induced [17, 80-82]. 
Figure I.5 – The NKG2D receptor and its ligands
Natural-killer group 2, member D (NKG2D) is constitutively expressed by NK cells in both humans and mice. In hu-
mans, NKG2D associates exclusively with the adaptor protein DAP10, assembling a hexameric complex.  In mice, al-
ternative	splicing	of	NKG2D	results	in	both	a	long-form	(NKG2D-L)	which	can	associate	with	DAP10,	or	a	short-form	
(NKG2D-S) which can associate either with DAP10 or DAP12.  In mice NKG2D mediated signaling depends on if the 
NKG2D receptor is associated either with DAP10 or DAP12.  There are seven NKG2D ligands expressed in humans 
and mice.  All of the ligands have MHC-I related domains.  NKG2D ligands are expressed at the cell surface in response 
to	cellular	stress	which	can	be	caused	by	factors	such	as	DNA	damage	and/or	viral	infection.	
DAP10 signaling
 DAP10 mediates NKG2D signaling via a 21 amino acid signaling motif (YINM), 
which is capable of binding either the p85 subunit of phosphatidylinositol-3-OH kinase 
(PI3K) or growth factor receptor bound protein 2 (GrB2) when phosphorylated[17].  These 
two signaling pathways haven been seen to play different, yet collaborative roles.  Abrogat-
ing the binding capacities of either the p85 subunit or inhibiting Grb2 signaling via the dis-
ruption of the Vav-1 protein induces both impaired NKG2D mediated cytotoxicity and de-
fective actin cytoskeleton reorganization after target-cell contact [83-85] (Figure I.6).
	 DAP10	has	also	been	seen	to	play	a	role	in	IL-15	mediated	signaling.		It	has	been	shown	
that	transgenic	NK	cells	lacking	the	DAP10	signaling	subunit	have	defective	IL-15	responsive-
ness	 [86].	 	This	defect	 in	 IL-15	 responsiveness	was	due	 to	 the	coupling	of	DAP10	and	 IL-15	
receptor	signaling	in	NK	cells.		Indeed,	not	only	does	DAP10		interact	with	the	IL-15R	complex,	
but	 its	 absence	 completely	 abolishes	STAT5	mediated	 signaling	via	 the	 IL-15	 receptor	 in	NK	
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cells	[86].	STAT5	is	a	member	of	the	STAT	family	of	proteins,	which	signal	via	the	JAK/STAT	pathway.	
STAT5	is	central	to	the	modulation	and	signaling	of	the	IL-15	receptor	after	stimulation	with	IL-15	[87].	
Role of PI3K in Natural Killer Cells and NKG2D signaling
 Class I PI3K enzymes are formed by a p110 catalytic subunit and a regulato-
ry subunit; the p110 subunit catalyzes formation of phosphatidylinositol P2 and phospha-
tidylinositol P3 after receptor stimulation.  Class Ia are heteorodimeric molecules com-
posed	 of	 a	 p110	 catalytic	 subunit	 (α,	 β,	 or	 δ)	 and	 a	 p85-like	 regulatory	 β	 subunits	 (p50α,	
p55α,	 p85α,	 p85β).	 	 The	 expression	 of	 p85α	 and	 p85β	 have	 been	 seen	 to	 be	 ubiquitous,	
unlike the p50 and p55a subunits whose expression is restricted to certain tissues [88]. 
Figure I.6 – NKG2D-DAP10 signaling pathway in NK cells
NKG2D	activation	leads	to	the	recruitment	of	the	p85	regulatory	subunit	of	PI3K	and/or	to	the	recruitment	of	the	Grb2/
VAV complex to the phosphorylated YINM motif in the cytoplasmic domain of DAP10.  These events are then capable 
of	various	downstream	kinases,	such	as	AKT,	ERK,	and	JNK	which	initiate	and	control	events	such	as	F-actin	polym-
erization, NK cell survival, and NK cell mediated cytotoxicity.
 Various studies have already shown the importance of the PI3K pathway in NK cells. 
Studies using both knockout and knockin mouse models have already shown the role of the 
p110γ	and	p110δ	PI3K	subunits	 in	NK	cell	maturation,	development	and	cytokine	generation	
[89-91].		However	little	is	known	about	the	potential	role	that	the	p85β	subunit	has	in	NK	cells,	
even though the importance of the p85 binding site, as previously stated, has already been re-
ported.  The abrogation of the p85 binding site abrogates DAP10 mediated cytotoxicity in hu-
man natural killer cells [92]. It still remains to be ascertained though if the p85 binding site 
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binds	either	the		p85α,	p85β	or	both	subunits.	p85β	has	already	been	reported	to	bind	with	greater	
affinity	 to	CD28	 rather	 than	 p85α	 in	murine	T	 cells,	 and	 it	 has	 also	 been	 reported	 to	 be	 im-
plicated in the internalization of the KIT receptor in mast cells, thus prompting the question 
if whether or not it might also have a role in mediating NKG2D receptor signaling [93, 94]. 
Objectives

37
 
 The principal objectives that were established at the beginning of this experimental the-
sis	were	the	following:
	 1)	 Phenotypically	and	functionally	characterize	NK	cells	in	murine	SLE-like	mo-
dels both in target and non-target organs of the disease.
	 2)	 Ascertain	if	NKG2D	ligands	are	expressed	in	the	kidneys	of	healthy	and/or	
diseased	murine	SLE-like	models	and	if	they	correlate	with	glomerulonephritic	onset.
	 3)	 Characterize	the	NK	cell	population	in	p85β	knockout	mice	and	analyze	the	
possible	functions	of	the	p85β	subunit	of	PI3K	in	NKG2D	signaling

Materials and Methods
Nullius addictus iurare in verba magistri
Horace
It	is	the	rule	which	says	that	the	other	rules	of	scientific	procedure	must	be	designed	in	such	a	
way	that	they	do	not	protect	any	statement	in	science	against	falsification.	
Karl Popper
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Mice
	 Female	 C57BL/6J,	 MRL/MpJ,	 and	 MRL/MpJlpr	 (Jackson	 Laboratories)	 mice	 were	
maintained	in	the	CNB	animal	facility	in	pathogen-free	conditions,	and	were	sacrificed	at	9,	15,	
or 52 weeks of age. FVB-121, FVB-187 and their respective wildtype littermates were gene-
rated as previously described [95].  They were bred and maintained by facilities pertaining to 
either	Cancer	Research	UK	or	 the	 Peter	Gorer	Department	 of	 Immunobiology	 (King’s	Colle-
ge).	 	All	 animal	 studies	 performed	 in	 the	UK	were	 in	 compliance	with	 the	UK	Home	Office.
	 p85β	 deficient	 mice	 (p85β-/-)	 were	 generated	 via	 the	 disruption	 of	 the	 first	
exon of the Pik3r2 gene by homologous recombination, as has been previously descri-
bed [96].  They were maintained in the CNB animal facility in pathogen-free conditions.
 All animal studies were approved by the CNB Ethics Committee for Animal Experimen-
tation	(Ref.	11022	and	Ref.	12033)	in	compliance	with	national	and	European	Union	legislation.	
Cell lines
 CHO cells were cultured in F-12 medium with 10% FBS.  YAC-1 cells (American 
Type	Culture	Collection)	were	 cultured	 in	RPMI	 1640	with	 10%	FBS.	 	RMA/S	 cells	 (a	 kind	
gift	of	Dr.	B.	Chambers,	Karolinska	Institute,	Stockholm,	Sweden)	were	cultured	in	RPMI	1640	
with	10%	FBS	and	2	mM	L-glutamine.S2	 cells	 (a	 king	gift	 of	Dr.	E	Long,	National	 Institute	
of Allergy and Infectious Diseases, Maryland, USA) were cultured in Schneider`s Drosophila 
Medium	with	L-glutamine	 (Lonza)	with	10%	FBS.	S2	 cells	were	grown	 in	 a	 27°C	 incubator.	
Stably	transfected	S2	cells	were	cultured	in	10%	FBS	and	0.5	mg/ml	of	G418	(Genycell	Biotech).
Generation of stable S2 Cell lines
	 The	plasmid	 for	 the	constitutive	expression	of	MULT-1	and	mICAM1	in	S2	cells	was	
the pAc5.1-V5-His plasmid (Invitrogen) whose expression is driven by the Drosophila Ac-
tin 5 promoter.  The pAc5.1–V5–His-mICAM1 (with the murine ICAM1 cloned insert) plas-
mid	was	 a	 kind	 gift	 from	Dr.	 E.	 Long.	The	 pAc5.1–V5–His-Mult1	 plasmid	 (with	 the	murine	
MULT-1	 cloned	 insert)	was	generated	with	 the	 following	 strategy.	The	pcr4-MULT-1	plasmid	
(IRCKp5014H065Q;	imaGenes)	was	digested	with	the	XcmI	enzyme	(New	England	Bioscien-
ce) and the ends blunted using Klenow enzyme (New England Bioscience). The plasmid was 
then	digested	with	XbaI	(New	England	Bioscience)	and	the	MULT-1	insert	was	extracted.		The	
pAc5.1-V5-His plasmid was digested with XcmI, and the ends blunted with Klenow enzyme. 
The	 pAc5.1-V5-His	 plasmid	was	 then	 digested	with	Xba-1,	 and	 the	MULT-1	 insert	 from	 the
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pcr4-MULT-1	 plasmid	 subcloned	 and	 ligated	 into	 the	 pAc5.1-V5-His	 plas-
mid	 using	 T4	 DNA	 Ligase	 (New	 England	 Bioscience).	 	 Resulting	 clones	 were	 con-
firmed	 by	 sequencing	 using	 the	 AC5	 Forward	 (5’	 ACACAAAGCCGCTCCAT-
CAG	 3’)	 and	 the	 BGH	 Reverse	 (5’	 TAGAAGGCACAGTCGAGG	 3’)	 primers.
Stable	 transfectants	of	S2-Mult1,	S2-Mult1/mICAM1,	S2-mICAM1,	were	generated	via	 trans-
fection of the pAc5.1-V5-His-mICAM1 and pAc5.1-V5-His-Mult1 plasmids with the Calcium 
Phosphate	 Transfection	 Kit	 (Invitrogen).	 Briefly,	 S2	 cells	 (1*106) were plated in a well of a 
6-well	plate	O/N,	and	the	day	of	transfection,	per	each	transfection,	19	μg	of	DNA	and	1	μg	of	
pNeofly	(selection	plasmid	for	neomycin)	[97]	were	added	to	a	2	M	CaCl2	mixture	and	then	to	
HBS.  This transfection mix was then added dropwise to the S2 cells, and the cell medium was 
changed after 24 hours.  G418 as a selection marker for transfection was added after 48 hours, 
and	 transfection	efficiency	was	assayed	via	flow	cytometry	(Figure M.1). In order to equalize
Figure M.1 – Expression of murine ligands on transfected S2 cells
Schenider	Drosophila	2	cells	(S2)	were	stably	transfected	with	plasmids	containg	murine	ICAM1	(mICAM1)	and/or	the	
MULT-1	NKG2D	ligand.		S2	cells	were	maintained	in	G418	for	selection	of	positively	transfected	cells.		S2	cells	were	
stained	with	fluorochrome-conjugated	anti-ICAM1	or	anti-MULT-1	mAb	and	analyzed	via	flow	cytometry.
levels	of	expression	of	MULT-1	and	mICAM1	between	single	and	double	positive	S2	cells,	transfected	S2	
cells	were	sorted	based	on	the	expression	levels	of	mICAM1	and	MULT-1.	S2-mICAM1,	S2-MULT-1,	
and	S2-MULT-1/mICAM1	cells	were	stained	for	either	mICAM	and/or	MULT-1	on	a	FACS	Aria	Ilu	
Cell sorter (Beckton Dickinson) and levels of expression were checked after 2-3 weeks post sorting. 
Cell isolation
 Single-cell suspensions of mouse spleen and BM (from tibiae and femur) were obtained 
by	passing	 suspensions	 through	a	40	μm	nylon	cell	 strainer,	 followed	by	 lysis	of	erythrocytes
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using an erythrocyte lysing buffer for 5 minutes at room temperature.  To obtain kidney lympho-
cytes,	decapsulated	kidneys	were	minced,	digested	with	10	μg/ml	collagenase	D		(Roche;	37°C,	10	
min),	passed	through	a	40	μm	nylon	cell	strainer	and	washed	3	times	with	50	ml	PBS	with	3%	FBS	
and	2	mM	EDTA.		Cells	were	resuspended	in	RPMI	with	3%	FBS,	gently	overlaid	on	Ficoll	(GE	
Healthcare),	and	centrifuged	(700	x	g,	20°C,	20	min).		Kidney	lymphocytes	were	isolated	from	the	
interface and washed twice with PBS.  Kidney lymphocytes were counted using a hemocytometer, 
and the absolute number of NK, CD3, CD4, and CD8 cells in kidneys was calculated by multiplying 
total	kidney	lymphocytes	by	the	percentage	of	positive	cells	as	determined	by	flow	cytometry.
Cell staining and flow cytometry
	 Antibodies	to	the	following	antigens	were	used	for	staining:	B220	(RA3-6B2;	Beckman	
Coulter),	 CD4	 (GK1.5;	 eBioscience),	 CD8	 (53-6.7;	 eBioscience),	 CD54	 (YN1/1.7.4;	 eBios-
cience),	MULT-1	(5D10;	eBioscience),	Ly-6G/Ly-6C	(RB6-8C5;	Biolegend),	NKp46	(29A1.4;	
Biolegend),	 CD2	 (12-15;	 Southern	 Biotechnology),	 MULT-1	 (1D6),	 CD3	 (145-2C11;	 eBios-
cience),	NKG2D	(A10;	eBioscience);	CD11a	 (2D7),	CD11b	 (3A33),	CD27	 (LG.3A10),	CD43	
(S7),	 CD49b	 (DX5),	 CD51(RMV-7),	 CD107a	 (1D4B),	 CD122	 (5H4),	 CD45	 (I3/2.3),	 IFNγ	
(XMG1.2),	TER119	 (TER119),	Ly49A+Ly49D	 (12A8),	Ly49C+Ly49I	 (14B11),	Ly49D	 (4E5),	
Ly49F	(HBF-719),	Ly49G	(4D11),	pSTAT5	(pY694)	were	all	purchased	from	BD	Biosciences.	
Dead	cells	were	distinguished	using	the	Live/Dead	Fixable	Dead	Cell	Stain	(L34955,	Invitrogen).
 Natural killer precursor cells were gated on the CD122+Lin-	 (Lineage)	 gate,	 in	which	
the	Lin	panel	included	the	following	antibodies:	anti-B220,	-CD3,		CD11b,		Ly-6G/Ly-6C,	and	
TER119.		Stained	cells	were	analyzed	in	a	Gallios	(Beckman	Coulter)	flow	cytometer	and	data	
analyzed	 with	 Kaluza	 v.	 1.0	 (Beckman	 Coulter)	 and	 FlowJo	 v.	 8.0	 (Treestar	 Inc.)	 software.
NK cell isolation
 Single-cell suspensions from spleen and BM were passed through nylon wool co-
lumns to deplete adherent populations consisting of B cells and macrophages [98].  Nylon 
wool	 non-adherent	 cells	 were	 then	 purified	 with	 the	 CD49b	 microbead	 or	 the	 anti-NKp46	
microbead	 kits	 (Miltenyi	 Biotech).	 	 Cells	 were	 cultured	 with	 20	 nM	 murine	 IL-15	 or	 mu-
rine	 IL-2	 (1000	U/ml)	 (both	 from	Peprotech)	 in	RPMI	with	 10%	FBS,	 penicillin,	 streptomy-
cin,	 L	 glutamine,	 sodium	 pyruvate,	 non-essential	 amino	 acids,	 and	 beta-mercaptoethanol.
44
Conjugation assays
	 Six-day	 IL-15-cultured	 or	 IL-2-cultured	 NK	 cells	 were	 tested	 for	 purity	 and	 used	
in conjugation assays.  For conjugation assays, spleen and BM NK cells were stained with 
PH26	 Red	 Fluorescent	 Cell	 Linker,	 and	 YAC-1	 or	 S2-mICAM1	 cells	 with	 PKH67	 Green	
Fluorescent	 Cell	 Linker	 (both	 from	 Sigma-Aldrich).	 	 NK	 and	 target	 cells	 were	 coincu-
bated	 at	 a	 1:2	 ratio	 (37°C,	 various	 times),	 fixed	 in	 1%	 paraformaldehyde,	 and	 analyzed	 by	
FACS.	 	 Events	 positive	 for	 red	 and	 green	 fluorescence	 were	 considered	 conjugates,	 and	 the	
percentage	 of	 conjugation	 was	 calculated	 as	 (conjugated	 NK	 cells/total	 NK	 cells)	 ×	 100.	
CD107a degranulation Assays
	 Six-day	 IL-15-cultured	 or	 IL-2-cultured	 NK	 cells	 were	 tested	 for	 purity	 and	 used	
in	 degranulation	 assays.	 	 2	 x	 105	NK	cells	were	 incubated	 at	 a	 1:2	 ratio	with	different	 target	
cells	 (37°C,	4	h)	with	10	μg/ml	monensin	 (Sigma)	and	5	μl	CD107a-FITC-conjugated	antibo-
dy or an isotype control.  Cells were washed and stained with anti-NKp46 and -CD3 antibo-
dies.  The percentages of CD107a-positive NKp46+CD3-	cells	were	analyzed	by	flow	cytometry
Natural Killer Cytotoxicity FACS Assay
	 Six-day	 IL-2-cultured	NK	cells	were	 tested	 for	purity	and	used	 in	cytotoxicity	assays.	
For	 cytotoxicity	 assays,	 target	 cells	were	 stained	with	 PKH67	Green	 Fluorescent	Cell	 Linker	
(Sigma-Aldrich).	 	NK	 and	 target	 cells	were	 coincubated	 at	 various	 ratios	 (1:1,	 1:3,	 1:5,	 1:10,	
1:20)	in	200	μl	total	volume	for	4	hours	at		37°C.		Each	condition	was	done	in	duplicate.		The	
reaction was stopped by adding 400ul of ice-cold PBS-staining and placing the tubes on ice. 
15	ul	of	PI	was	added	 to	each	cell	before	passing	 the	 tube	on	 the	flow	cytometer.	Target	cells	
were	gated	for	bright	positivity	on	 the	FL1	gate.	 	The	percentage	of	specific	 lysis	of	each	 tar-
get	 cell	 in	 each	 condition	was	 calculated	 by	 applying	 the	 following	 formula:	 	 (100x(%PI	 po-
sitive	cells	-	%	Spontaneous	death)/(100	-	%	Spontaneous	Death)).	 	A	positive	control	for	cell	
death consisting of only target cells incubated with 3% H202 was included in every experiment.
Intracellular IFN-γ staining
	 Freshly	isolated	kidney	lymphocytes	in	RPMI	1640	supplemented	with	10%	FBS	were	
cultured	with	PMA	(P8139;	Sigma;	25	ng/ml),	ionomycin	(I0634;	Sigma;	1	μg/	ml),	and	brefeldin	
A	(420601;	Biolegend;	1X)	 (4	h,	37°C,	5%	CO2).	 	Cells	were	harvested	after	culture,	 stained	
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with	antibodies	to	surface	antigens	(30	min,	4°C),	fixed	with	4%	paraformadehyde,	permeabilized	
with	PBS	0.5%	saponin,	and	stained	for	IFN-γ	(diluted	in	permabilization	buffer,	30	min,	room	
temperature	(RT)).		Cells	were	washed	once	with	permeabilization	buffer	and	analyzed	by	flow	
cytometry.  Control isotypes were included in all experiments for intracellular cytokine detection.
pSTAT5 staining
 Freshly isolated kidney lymphocytes and single cell suspensions from spleen 
and	BM	were	washed	 and	 incubated	 (15	min)	 in	RPMI	 1640	 alone	 or	with	 20	 nM	 recombi-
nant	 murine	 IL-15;	 the	 reaction	 was	 terminated	 by	 adding	 the	 same	 amount	 of	 BD	 Cyto-
fix	 buffer	 (554655;	 BD	 Biosciences).	 	 Cell	 suspensions	 were	 washed,	 permeabilized	
with BD PhosphFlow Perm Buffer III (558050; BD Biosciences), and stained for surfa-
ce	 antigens.	 	Cells	were	 then	washed,	 and	 stained	with	 pSTAT5	 (pY694)	 diluted	 1:1	 in	 PBS.
Total Organ Elisa
	 Mice	were	 sacrificed,	 and	 the	 kidneys	 of	 the	mice	 of	 each	 group	were	 exiced,	weig-
hed,	 and	 finely	minced.	 	Kidneys	were	 then	 plated	 in	 2	ml	 of	RPMI	with	 10%	FBS,	 penici-
llin,	streptomycin,	L	glutamine,	sodium	pyruvate,	non-essential	amino	acids,	and	beta-mercap-
toethanol	at	37°C	for	24	hours.		Supernatants	were	collected,	and	spun	down	three	times	at	300	
x	RCF	 in	 order	 to	 remove	 cellular	 debris.	 	The	 supernatants	were	 then	 tested	 in	 triplicate	 for	
IL-15	 (eBioscience	Mouse	 IL-15/IL-15R	Complex	ELISA	Ready-SET-Go!),	CXC3CL1	 (RnD	
Systems	 Mouse	 CX3CL1/Fractalkine	 DuoSet),	 and	 IL-12	 (BD	 OptEIA	 Mouse	 IL-12	 (p70)	
ELISA	 Set).	 	The	 final	 concentration	was	 then	 normalized	 to	 the	 total	weight	 of	 each	 organ.	
Immunohistochemistry and immunofluorescence antibodies and reagents
	 We	used	 rat	 anti-mouse	Ly49G2	 (4D11,	 1/100;	 eBioscience),	 goat	 anti-mouse	NKp46	
(AF2225,	 1:100;	 R&D	 Biosytems),	 rat	 anti-mouse	 CD8	 (YTS169.4,	 1/100;	 abcam),	 rat	 anti-
mouse	CD4	(RM4-4;	1:100;	Biolegend),	goat	anti-mouse	Rae1γ	(AF1136,	1:100;	R&D	Biosys-
tems),	 rabbit	 anti-mouse	 synaptopodin	 (1:200;	Synaptic	Systems),	 rat	 anti-mouse	Mult1	 (1D6,	
1:50),	goat	anti-mouse	H60	(C-20;	Santa	Cruz	Biotechnologies),	 rat	anti-mouse	H60	(205326;	
R&D	Biosystems),	goat	anti-human	MICA	(BAF1300,	15μg/ml;	R&D	Biosystems),	rabbit	anti-
human	ULBP1	 (1:30;	Novus	Biologicals),	donkey	anti-goat	 IgG	Alexa488,	donkey	anti-rabbit	
IgG	Alexa594,	mouse	anti-rat	Cy3	(all	 three	from	Jackson	ImmunoResearch),	and	DAPI.	 	Rat
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anti-mouse	 Mult1	 was	 a	 kind	 gift	 from	 Dr.	 S.	 Joncic	 (Univ.	 Rijeka,	 Rijeka,	 Croa-
tia) [99], aged NZBxNZW(F1) OCT-embedded kidney tissue sections were a kind gift 
from Dr. S. Izui (Univ. Geneva, Geneva, Switzerland), and three-month-old female 
BALB/c	 kidney	 tissue	 sections	 were	 a	 kind	 gift	 from	 Dr.	 M.	 Zonca	 (CNB,	 Madrid,	 Spain).
Immunohistochemistry protocol
	 Spleens	and	kidneys	were	extracted	and	snap-frozen	in	tissue-freezing	medium	(Jung).	
Sections	(10	μm)	were	acetone-fixed	(4°C,	10	min),	endogenous	peroxidase	was	blocked	(K4009;	
Dako;	7	min)	and	slides	incubated	with	primary	antibody	(2	h,	RT	or	overnight,	4°C),	followed	by	
rabbit	EnVision+	System	HRP	reagent	(Dako;	30	min),	rat	or	goat	Histofine	Simple	Stain	kits	(Ni-
chirei Biosciences; 30 min).  Frozen sections were stained with AEC+ substrate chromogen solu-
tion (Dako; 15-20 min) and hematoxylin-counterstained (Sigma-Aldrich; 3 min).  All mAb and an-
tisera were diluted in PBS with 10% FBS and 2.5% BSA, and used at concentrations determined to 
yield	optimal	staining.		HRP-conjugated	polymer-stained	sections	were	used	as	negative	controls.
	 Formalin	 fixed	 kidney	 sections	 from	 six	 patients	 with	 confirmed	 active	 Stage	 III-IV	
Lupus	Nephritis	were	 stained	 for	ULBP1	and	MICA	expression.	Sections	were	deparaffinized	
in	xylene	and	rehydrated	 in	EtOH.	Heat	 Induced	Antigen	Retrieval	was	performed	using	Tris-
EDTA (ph 9.0) for 20 minutes in a water steamer.  Sections were washed, endogenous peroxi-
dase	 blocked,	 and	 primary	 antibodies	 for	MICA	 and	ULBP1	 left	 overnight	 at	 4°C.	 	 Sections	
were	 washed,	 and	 staining	 was	 followed	 by	 rabbit	 EnVision+	 System	HRP	 reagent	 (DAKO;	
30	min)	or	Vectastain	Elite	ABC	Kit	(Vector	Laboratories;	30	min).	Sections	were	stained	with	
AEC+ substrate chromogen solution (Dako; 15-20 min) and hematoxylin-counterstained (Sig-
ma-Aldrich;	3	min).	HRP-conjugated	polymer-stained	sections	were	used	as	negative	controls.
Quantification of Rae-1 staining intensity in glomeruli
 Chromogen deposition was measured by quantitative immunohistochemistry using an es-
tablished	method	[100].		In	brief,	images	of	glomeruli	(100x	magnification)	from	various	mice	
were	acquired	in	a	Leica	microscope	(vertical	Leitz	DM	RB)	with	an	adapted	Olympus	(DP70)	
camera;	 image	files	were	saved	 in	a	 tagged-image	file	 format.	 	The	amount	of	chromogen	per	
pixel was determined by selecting the glomeruli in a 200 x 200 pixel region and subtracting the 
mathematical energy (EM) of the control slide (not exposed to primary antibody) from that of 
a	homologous	glomerulus	on	the	experimental	slide	(exposed	to	Rae-1	antibody).	 	Chromogen	
quantity	(EM)	is	expressed	as	energy	units	per	pixels	(eu/pix).		We	analyzed	25	glomeruli	from	
47
each mouse in every group.  Data are represented as mean ± SD. 
Statistical	analysis	was	performed	using	a	two-tailed	Student’s	t-test.
Immunofluorescence and confocal analysis
	 Kidney	 sections	 (10	 μm)	 were	 acetone-fixed	 (4°C,	 10	 min),	 blocked	 with	 serum	 (2	
h),	 incubated	 with	 primary	 antibodies	 (RT,	 2	 h),	 followed	 by	 secondary	 antibodies	 (RT,	 45	
min). Cells were washed in TBS, incubated with DAPI (15 min), and mounted with Fluoro-
mount	G	 (Southern	Biotech).	 	Confocal	 analysis	was	performed	on	a	Leica	SP5	confocal	mi-
croscope.	 	 Entire-tissue	 section	 pictures	 were	 analyzed	 via	 immunofluorescence	 using	 a	 Lei-
ca	 DMI	 6000B	 inverted	 microscope	 and	 the	 Leica	 Application	 Suite	 Microscope	 Software	
to create a full processed image.  All samples include appropriate antibody staining controls.
Quantification of stained area and statistical analysis
	 Stained	 areas	 were	 quantified	 using	 ImageJ	 (100x).	 	 For	 quantification	 of	 the	 to-
tal stained areas of kidneys, 50 representative sections were analyzed from 5 mice from each 
group.  To quantify the percentage of glomeruli with NKp46+, CD4+, or CD8+	 infiltration,	
25	 random	field	 sections	were	analyzed	 for	5	mice	 from	each	group.	 	 In	each	 section,	 the	 to-
tal number of glomeruli was counted, then divided by the number of glomeruli which showed 
at least one positive-staining AEC cell inside the glomeruli.  Data are represented as mean ± 
SD.	 Statistical	 analysis	 was	 performed	 using	 a	 two-tailed	 Student’s	 t-test.	 	 Data	 were	 con-
sidered	 significantly	 different	 at	 a	 value	 of	 p	 <0.01	 and	 highly	 significant	 at	 p	 <0.001.
NK cell BrdU proliferation assay
 Splenic NK cells were cultured for 6 days, harvested, and seeded into a 6 well pla-
te	 (2*106	 cells/well)	 in	 complete	 RPMI	 medium	 for	 2	 hours.	 	 BrdU	 was	 then	 added	 to	
a	 final	 concentration	 of	 10	 μM,	 and	 cells	 were	 incubated	 for	 4	 hours.	 	 Cells	 were	 then	
surface	 stained	 for	NKp46,	CD3	 on	 ice	 for	 30	minutes,	washed,	 and	 then	 fixed	with	 1%	 pa-
raformaldehyde-0,01%	Tween-20	 in	PBS	while	vortexing.	 	Cells	were	 incubated	at	RT	 for	30	
minutes and then for 30 minutes on ice.   Cells were washed, and resuspended in a solution 
containing	 50	Kunitz	DnaseI/ml	 (0,15M	NaCL,	 3,2	mM	MgCl,	 10	 μM	Hcl).	 	 Cells	were	 in-
cubated	 for	 10	 inutes	 at	 RT,	 washed,	 and	 stained	 with	 anti-BrdU-FITC	 (BD	 Biosciences).	
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IFN-γ Elisa
	 Wells	of	96	well-flat	bottom	plates	were	coated	overnight	at	4°C	with	10	μg/ml	of	either	
anti-NKG2D (A10) or anti-NK1.1 (PK136) mAbs in PBS.  Plates coated only with PBS served as 
controls.		Wells	were	washed	three	times	with	PBS,	and	2*105	IL-2-activated	splenic	NKp46+CD3- 
cells were plated per well for 4 hours.  After 4 hours the supernatants were collected,  and tested in 
triplicate	for	IFN-g	via	a	commercially	available	ELISA	kit	(BD	OptEIA	Mouse	IFN-γ	ELISA	Set).	
NKG2D Downregulation Assay
	 NKG2D	downregulation	assays	were	performed	with	six	day	IL-2-activated	spleen	de-
rived	NK	cells	from	p85β-/-	and	WT	mice.		1*106 cells per condition were stimulated on ice, in 
ice-cold	PBS	with	10	ug/ml	NKG2D	A10	activating	antibody	for	15	minutes.		The	reaction	was	
stopped	by	adding	200	ul	of	ice-cold	PBS	and	cells	were	spun	down	for	5	min	x	300	RCF	at	4°C.	
Cells	were	then	incubated	with	an	anti-hamster	IgG2b	antibody	(G94-56)	at	37°C	in	a	warm	water	
bath	at	various	time	points.		Reaction	was	stopped		by	adding	double	the	volume	of	PFA	4%.		Cells	
were	then	stained	for	30	minutes	at	4°C	with	anti-CD3,	-NKp46,	-NKG2D	(CX5	clone)	antibodies.	
Cells	were	then	analyzed	via	flow	cytometry.		The	percent	of	downregulation	in	each	condition	was	
calculated relative to the MFI of NKG2D staining of cells which had been stopped at time point 0.
qRT-PCR analysis of gene expression
	 RNA	was	extracted	from	six	day	IL-2	activated	spleen	derived	NK	cells	from	C57BL/6	
mice.		RNA	was	extracted	from	NK	cells	using	the	Purelink	RNA	mini	kit	(Ambion	Lifesciences).	
cDNA	was	obtained	using	total	RNA	using	the	High	Capacity	cDNA	Reverse	transcription	kit	
(Applied	Biosciences).		Oligonucleotide	primers	used	were	of	murine	p85α	(Forward:	CATCTC-
CAAGTCCACTGACG	Reverse:	GAATGTTCGACTCTATACAGAACACAA),	p85β	(Forward:	
GCGGTAGATGACACAGTGCTT	 Reverse:	 GGGCTGTTACGCATGCTC),	 and	 β-actin	
(Forward:	 GGCTCCTAGCACCATGAAGA	 Reverse:	 CCACCGATCCACACAGAGTA).	 PCR	
reactions	contained	Power	SYBR	Green	RT	MasterMix	(Applied	Biosciences)	and	amplification	
was	performed	in	an	ABI	PRISM	7900HT	(Applied	Biosystems).	Amplification	was	performed	
at	95ºC,	10	min;	40	cycles,	95ºC,	15	sec;	60ºC,	20	sec;	72ºC,	30	sec.	mRNA	levels	were	quanti-
fied	using	the	2-ΔCt	method	and	normalized	to	β	actin.		Results	were	analyzed	using	SDS	v2.2.2.
  
Results
Just	because	an	idea	is	true	doesn’t	mean	it	can	be	proved.	And	just	because	an	idea	can	be	
proved	doesn’t	mean	it’s	true.”	
Jonah	Lehrer
You	always	admire	what	you	really	don’t	understand.
Blaise Pascal
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Part 1   NK cell characterization in the MRL mouse strain
1.1 Natural killer cell cellularity in the MRL mouse strain
	 The	MRL	mouse	strain	spontaneously	generates	a	lupus-like	phenotype,	one	of	the	main	
effects	of	which	is	severe	glomerulonephritis.		MRL/MpJ	(MPJ)	mice	develop	this	phenotype	spon-
taneously	at	~12	months	of	age,	whereas	MRL/MpJlpr	(LPR)	mice,	which	have	the	same	genetic	
background but which generated a spontaneous homozygous mutation in the Fas allele, develop 
similar	but	more	severe	symptoms	by	~3-4	months	of	age	[101].		However,	while	the	LPR	mouse	
has	been	extensively	used	as	a	SLE-like	model,	scarce	data	is	found	in	the	literature	using	the	MPJ	
mouse	as	a	model	for	the	study	of	SLE.		The	limited	phenotypic	characterization	of	NK	cells	in	a	
SLE	environment	prompted	us	to	characterize	the	NK	cell	population	in	BM	(BM)	and	spleen	from	
healthy	and	diseased	MPJ	and	LPR	mice;	this	would	allow	us	to	assess	whether	defects	reported	in	
the periphery (spleen) are also found in BM, where NK cells develop.  We analyzed total splenocyte 
and	BM	cell	numbers	in	predisease	LPR	(9-week-old),	diseased	LPR	(3-	to	4-month-old),	healthy	
MPJ	(3-	to	4-month-old)	and	diseased	MPJ	(1-year-old)	mice.		Nine-week-old	LPR	mice	were	used	
as	a	pre-disease	model	due	to	absence	of	skin	lesions,	inflammation	or	cell	proliferation	in	kid-
neys.		One-year-old	MPJ	mice	were	sacrificed	as	soon	as	severe	skin	lesions	appeared.		As	predict-
ed,	significantly	larger	numbers	of	splenocytes	were	seen	in	diseased	and	pre-diseased	LPR	mice	
(splenomegalia	is	a	common	feature	due	to	the	LPR	mutation)	compared	to	healthy	and	diseased	
MPJ	mice	(Figure R.1A).  We found no difference in total splenocyte number between healthy and 
diseased	MPJ	mice,	and	no	differences	in	total	BM	cellularity	between	groups	(Figure R.1A,B).
 To determine the proportion of NK cells in spleen and BM, we gated the NKp46+CD3- cell 
population.		NKp46	belongs	to	the	natural	cytotoxicity	receptor	family	and	is	expressed	specifi-
cally on NK cells and a subset of NK-like T cells [102, 103].  Furthermore, its expression does 
not appear to be strain-dependent, at difference from the NK1.1 protein which is not expressed 
in	the	MRL	background	[102].		We	observed	a	significant	reduction	in	the	percentage	of	spleen	
NKp46+CD3-	cells	in	diseased	LPR	mice	compared	to	prediseased	LPR	and	all	MPJ	mice;	there	
was	also	a	difference	between	diseased	and	healthy	MPJ	mice	(Figure R.1E).	Diseased	MPJ	mice	
show	significantly	lower	total	spleen	NKp46+CD3- cell numbers than any of the other groups (Fig-
ure R.1F); no differences were found in total NKp46+CD3- cell numbers in the other groups.  There 
were no differences in total number or percentage of NKp46+CD3- cells in BM (Figure R.1G,H).
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Figure R1 - Analysis of absolute and relative NK cell numbers in bone marrow and spleen of healthy 
and diseased SLE-like mice
A,B) Spleens and bone marrow (tibiae and femur) were isolated from mice, and the total number of cells from both 
spleen (a) and bone marrow (b) were counted using a haematocytometer. Freshly isolated mouse splenocytes and bone 
marrow	cells	were	stained	with	anti-NKp46,	-CD45	and	-CD3	mAb.		C,D)	Representative	flow	cytometric	density	plots	
show the proportion of NK cells in the four mouse groups in both spleen (c) and bone marrow (d).  E,F,G,H) Cumulative 
data representative of the mean percentage (e,g) and total number of NKp46+CD3- cells (f,h) in both spleen and bone 
marrow	of	stained	NK	cells	in	all	four	groups.	Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	
SD;	n	=	4	to	8	mice/group	in	three	to	six	independent	experiments;	*p<0.05).
1.2 Natural killer cell surface marker expression
	 To	 determine	whether	 the	 SLE-like	 environment	 affects	NK	 cell	maturation,	we	 ana-
lyzed the expression of developmental markers in fresh NK cells derived from BM and spleen. 
NK	cell	development	can	be	defined	as	a	five-	or	six-step	process,	based	on	the	expression	pat-
tern	of	cell	surface	markers	[9,	29].		Expression	of	the	IL-2	and	IL-15	receptor	γ	chain	(CD122)	
marks NK cell commitment in BM; CD122, as well as NKG2D and NK1.1 (not expressed in the 
MRL	strain)	are	the	earliest	known	NK	cell	markers	[9].		Integrins	such	as	CD49b	(α2	integrin),	
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CD11b (Mac-1) and CD43 (leukosialin), which are upregulated on and correlate with pheno-
typically mature NK cells, are also common developmental markers for these cells.  Gated 
NKp46+CD3- cells were analyzed for expression of these markers and of other known NK cell 
surface	markers,	such	as	CD2	(LFA-2)	and	CD11a	(LFA-1)	which	partake	in	the	formation	of	the	
NK cell immunological synapse [104].
Figure R2 - Cell surface analysis of mature NK cell markers in bone marrow and spleen of healthy 
and diseased SLE-like mice
A,C) NK cells were gated as CD45+NKp46+CD3- and stained for various NK cell markers.  A representative staining 
for	each	marker	is	shown	both	in	spleen	(a)	and	bone	marrow	(c).	Gates	were	set	using	unstained	or	nonspecific	isotype	
mAb	controls	(not	shown).	B,D)	The	median	fluorescence	intensity	for	each	markers	was	analyzed	for	both	spleen	(b)	
and	bone	marrow	(d)	samples.		Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	4	to	8	
mice/group	in	three	to	six	independent	experiments;		*p<0.05).
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CD2,	 CD11b,	 CD43,	 CD49b,	 and	 CD122	 were	 significantly	 downregulated	 in	 spleen	
NK	 cells	 from	 diseased	 LPR	 and	 MPJ	 mice	 compared	 to	 their	 healthy	 counterparts	 (Fig-
ure R.2).	 In	 BM,	 CD122	 and	 CD43	 were	 downregulated	 only	 in	 diseased	 MPJ	 and	 LPR	
mice	 compared	 to	 healthy	 MPJ	 but	 not	 to	 prediseased	 LPR	 mice.	 NKG2D	 and	 CD11a	 lev-
els were unchanged in BM and spleen NK cells from all mouse groups (Figure R.2).
1.3 Immature NK cells accumulate in the spleen of diseased SLE-like mice
 Based on the decrease in mature NK cell markers on peripheral mature NK cells, we 
postulated a defect in NK cell differentiation in the periphery.  NK precursor cells (NKP) are 
thought to arise in BM; they can differentiate fully and mature in BM, or travel to other organs 
and complete their differentiation in situ.  Indeed, NKP cells have been reported in peripheral 
organs of mice, including spleen [31].  NK cell differentiation is a complicated process that be-
gins in the BM with the generation of NKP cells, which are CD122+Lin-CD49b-NKp46-.  These 
cells then follow a developmental pattern that gives rise to immature NK (iNK) cells in which 
they	begin	to	express	some	but	not	all	NK-specific	developmental	markers:	CD122+Lin-CD49b-
NKp46-	(Stage	1	-	NKP)	→	CD122+Lin-NKp46+CD49b-	(Stage	2)	→	CD122+Lin-NKp46+CD49b+ 
(Stage 3) [1, 31, 105, 106].  After Stage 3, NK cells begin to express NK cell marker CD11b and 
become CD122+Lin-NKp46+CD49b+CD11b+ (Stage 4), and are considered Stage 4, mature NK 
cells.		Analysis	of	total	NKP	and	iNK	cell	numbers	in	BM	and	spleen	of	healthy	and	diseased	LPR	
and	MPJ	mice,	showed	accumulation	of	Stage	1,	Stage	2	and	Stage	3	cells	in	spleen	but	not	in	BM	
of	diseased	LPR	and	MPJ	mice	compared	to	healthy	MPJ	and	prediseased	LPR	mice	(Figure R.3).
1.4  CD11bHighCD27Low NK populations are greatly reduced in diseased SLE-like 
mice
 NK cell maturation can be further subdivided into another four-stage process, dependent 
on CD27 and CD11b expression [105].  Studies have shown a process in which the NK cell 
maturation pattern correlates with progressive acquisition of NK cell effector functions in mature 
NK	cells:	CD11bLowCD27Low	→	CD11bLowCD27High	→	CD11bHighCD27High	→	CD11bHighCD27Low.
 Freshly isolated BM and spleen cells were gated in NKp46+CD3- and analyzed for 
CD11b and CD27 expression.  We observed a severe reduction in CD11bHighCD27Low NK 
cells	 in	 spleens	 from	 diseased	 LPR	 and	MPJ	 compared	 to	 those	 from	 healthy	 LPR	 and	MPJ	
mice; this correlated with an increase in CD11bLowCD27High	 NK	 cells	 in	 diseased	 LPR	 and
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Figure R3 - Analysis of NKP and iNK cells in bone marrow and spleen of healthy and 
diseased SLE-like mice
A,B)	 Representative	 flow	 cytometric	 density	 plots	 show	 the	 proportion	 of	 CD122+LIN- cells.  Plots show propor-
tions of Stage 1 (CD122+LIN-NKp46-CD49b-), Stage 2 (CD122+LIN-NKp46+CD49b-) and Stage 3 (CD122+LIN-
NKp46+CD49b+) iNK cell groups in spleen (a) and bone marrow (b).  C,D) Absolute numbers were calculated of total 
Stage	1,	2,	and	3	iNK	cells.	Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	4	to	8	mice/
group	in	three	to	six	independent	experiments;	*p<0.05).
MPJ	mouse	spleens (Figure R.4A).	There	were	no	significant	differences	in	CD11bCD27	subsets	
in NK cells from fresh BM of any mouse tested (Figure R.4B).
1.5  Spleen and BM NK cells show slight conjugation defects
	 To	assess	whether	BM	and	spleen	NK	cells	in	a	SLE	environment	also	have	functional	defects,	
we	performed	conjugation	and	CD107a	degranulation	assays	using	6-day-cultured	IL-15-activated	
NK	cells	from	healthy	MPJ	and	diseased	LPR	mice.		NK	cells	were	not	activated	with	IL-2,	as	LPR	
mice	do	not	respond	well	to	IL-2	[107].		Conjugation	at	short	intervals	(0,	5,	10	and	20	min)	was	tested	
using YAC-1 NKG2D ligand-expressing target cells.  There were no differences in the conjugation 
capacity	of	BM	IL-15-activated	NK	cells	between	diseased	LPR	and	healthy	MPJ	mice.		Spleen	IL-
15	activated	NK	cells	from	diseased	LPR	mice	showed	conjugation	defects	at	20	min	(Figure R.5A).
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Figure R4 - Analysis of CD27 and CD11b subsets in bone marrow and spleen of healthy and diseased 
SLE-like mice
Freshly isolated mouse splenocytes and BM cells were stained with anti-NKp46 and -CD3 mAb and analyzed for 
CD11b	and	CD27	expression.		Representative	flow	cytometric	density	plots	show	the	percentage	of	CD11bCD27	NK	
cell subpopulations in splenocytes (A) and BM cells (C).  Percentages were calculated of CD11bLowCD27High, CD11b-
HighCD27High, and CD11bHighCD27Low cells for splenocytes (B) and BM cells (D). Data were analyzed with a two-tailed, 
unpaired	 Student’s	T	 test	 (mean	 ±	 SD;	 n	 =	 4	 to	 8	mice/group	 in	 three	 to	 six	 independent	 experiments;	 **p<0.01,	
*p<0.05).
1.6  BM and spleen NK cells from diseased LPR mice degranulate less CD107a 
than healthy MPJ mice
	 Degranulation	 of	 the	 lysosome-associated	 membrane	 protein-1	 CD107a	 (LAMP-
1) is upregulated on the NK cell surface following stimulation with target cells able to induce 
a cytolytic response.  As CD107a expression correlates with cytokine secretion and NK cell-
mediated lysis of target cells, we used this as a marker to determine whether NK cells from 
SLE	mice	 suffer	 from	 cytolytic	 defects	 [108].	 	As	 target	 cells,	we	 used	CHO	 (which	 express	
a	 homologue	 of	 H2-Dd),	 RMA/S	 (which	 express	 low	 levels	 of	 MHC	 class	 I),	 and	 YAC-
1 cells (which express NKG2D ligands).  After stimulation with all three target cell lines, 
both	 BM	 and	 spleen	 IL-15-activated	 NK	 cells	 from	 diseased	 LPR	 mice	 showed	 signifi-
cant decreases in CD107a+	 cells	 compared	 to	 those	 from	 healthy	MPJ	 mice	 (Figure R.5B).
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Figure R5 - CD107a and conjugation assays on IL-15 activated splenocytes and bone marrow cells 
from healthy and diseased SLE-like mice
A)	Six-day	IL-15-activated	spleen	or	BM	NK	cells	were	tested	in	a	four-point	conjugation	assay	against	YAC-1	target	
cells	at	a	2:1	target:effector	ratio.		Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	3	
mice/group	in	three	independent	experiments;	*p<0.05).	B,C)	Spleen	or	BM	NK	cells,	activated	as	above,	were	tested	
against	the	CHO,	RMA/S	and	YAC-1	target	cell	lines	at	a	2:1	target:effector	ratio	in	a	4	h	CD107a	degranulation	assay.	
Representative	stainings	are	shown	(B);	data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	
=	3	to	5	mice/group	in	three	independent	experiments;	*p<0.05)	
1.7  Characterization of kidney infiltrating NK and CD3 cells
 Having established the existence of NK cell maturation defects in BM and spleen from 
diseased	 SLE-like	 mice,	 we	 decided	 to	 analyze	 via	 flow	 cytometry,	 the	 lymphocyte	 popula-
tions of kidneys in our four mice models.  To date, the only information available on kidney 
infiltrating	lymphocytes	has	been	via	immunohistochemical	stainings,	and	to	our	knowledge,	no	
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complete analysis of these populations had been done comparing healthy and diseased kidneys
during an active disease state. 
	 Freshly	 ficoll-isolated	 lymphocytes	 from	 kidneys	were	 stained	 for	 CD45,	 CD3,	 CD4,	
CD8, NKp46, and various NK cell surface markers, and gated via the exclusion of dead cells 
and doublets (Figure R.6A,B).  Our analysis showed an increase in the absolute number of 
Figure R6 - Flow cytometric analysis of lymphocyte populations in the kidneys of healthy and dis-
eased SLE-like mice
Gating	strategy	for	Ficoll-isolated	kidney	 lymphocytes.	 	A)	Representative	gating	strategy	for	acquisition	of	Ficoll-
isolated	kidney	lymphocytes.		Briefly,	cells	were	gated	via	doublet	discrimination,	followed	by	live/dead	discrimina-
tion, followed by CD45 positivity, followed by debris discrimination. Cells were then gated on CD3+NKp46- subsets 
for	analysis	of	CD4	and	CD8	subsets.	B)	Representative	flow	cytometric	density	plots	show	the	proportion	of	NK	cells	
in the four mouse groups C,D) Cumulative data representative of the total number of CD45+ cells (c) and NK and CD3 
subpopulations (d). E,F) Cumulative data representative of the mean percentage of NK and CD3 cells (e) and of CD3 
subpopulations	(f).		Gates	were	set	using	unstained	or	nonspecific	isotype	mAb	controls	(not	shown).		Data	were	ana-
lyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	4	to	8/group;	three	to	four	independent	experiments,	
**p<0,01,	*p<0.05).
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CD45+	 cells	 infiltrating	 the	 kidneys	 of	 diseased	 LPR	 and	 MPJ	 mice	 compared	 to	 healthy	
and prediseased mice (Figure R.6C).	 	 We	 also	 show	 a	 significant	 increase	 in	 the	 to-
tal	 numbers	 of	 NK	 cells	 only	 in	 the	 kidneys	 of	 diseased	 LPR	 mice	 compared	 to	 all	 oth-
er groups (Figure R.6D).	 	 Prediseased	 LPR	 mice	 showed	 higher	 levels	 of	 NK	 cells	 com-
pared	 to	 healthy	 MPJ	 mice.	 	 The	 total	 number	 of	 CD45+CD3+CD4+, CD45+CD3+CD8+, 
CD45+CD3+CD4-CD8-	 cells	 was	 also	 found	 to	 be	 increased	 only	 in	 diseased	 LPR,	 but	
not	 diseased	 MPJ	 kidneys,	 compared	 to	 healthy	 and	 predisease	 controls	 (Figure R.6D).
1.8  Phenotypic characterization of infiltrating kidney NK cells
 An	 analysis	 of	 the	 phenotypic	 characterization	 of	 kidney	 infiltrating	 NK	
cells showed, in contrast to spleen and BM, no differences in NKG2D, CD122, CD2 
or CD49b expression in diseased mice compared to their healthy counterparts (Fig-
ure R.7B).	 	 CD11b	 and	 CD43	 levels	 were	 nonetheless	 increased	 in	 diseased	 MPJ	 and	
LPR	 NK	 cells	 compared	 to	 prediseased	 LPR	 and	 healthy	 MPJ	 NK	 cells	 (Figure R.7B).
Figure R7 - Phenotypic analysis of kidney infiltrating NK cells in healthy and diseased SLE-like mice
A) NK cells were gated as NKp46+CD3- and stained for various NK cell markers.  A representative staining is shown 
for	each	marker.	 	Gates	were	set	using	unstained	or	nonspecific	isotype	mAb	controls	(not	shown).		B)	The	median	
fluorescence	intensity	for	each	marker	was	analyzed.	Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	
(mean	±	SD;	n	=	4	to	8	mice/group	in	three	to	six	independent	experiments;	**p<0.01,	*p<0.05).	C)	Representative	flow	
cytometric density plots show the percentage of CD11bCD27 NK cell subpopulations D) Percentages of CD11bLowCD-
27High, CD11bHighCD27High, and CD11bHighCD27Low cells were calculated. Data were analyzed with a two-tailed, unpaired 
Student’s	T	test	(mean	±	SD;	n	=	4	to	8	mice/group	in	three	to	six	independent	experiments;	*p<0.05).
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	 The	 CD11b	 expression	 increase	 in	 diseased	 LPR	 and	MPJ	mice	 also	 correlated	 with	
significantly	larger	percentages	of	CD11bHighCD27Low cells compared to CD11bHighCD27High and 
CD11bLowCD27High cells (Figure R.7C,D).  We observed a clear tendency in CD11bLowCD27High cell 
accumulation	in	healthy	MPJ	and	prediseased	LPR	mice	compared	to	diseased	LPR	and	MPJ	mice.	
1.9  Functional characterization of infiltrating NK cells in kidney
	 To	 ascertain	whether	 infiltrating	NK	cells	 showed	 the	 same	defective	 functional	 char-
acteristics	as	 those	 in	periphery,	we	 tested	 for	 the	ability	of	 these	cells	 to	produce	 IFN-γ	after	
PMA/ionomycin	stimulation.		Significant	differences	in	the	percentages	of	IFN-γ	producing	cells	
in kidneys were found in the NK, but not CD4 or CD8 compartments. Kidney NK cells from 
diseased	MPJ	and	LPR	mice	had	a	 larger	percentage	of	cells	 that	 responded	 to	PMA/ionomy-
cin;	 furthermore,	 these	 cells	 secreted	more	 IFN-γ	 (as	measured	by	MFI)	 than	healthy	MPJ	or	
prediseased	LPR	 (Figure R.8A,C).	 	Moreover,	 the	difference	 in	 the	percentage	of	 IFN-γ	pro-
ducers was found in CD11bHighCD27Low cells, but not in the CD27High subset (Figure R.8B). 
1.10  Organ-specific induction of pSTAT5 in NK cells
 As NK cells suffer from impaired differentiation and maturation in spleen from 
diseased mice, but not in BM or kidney (where NK cells appear to have a more active phe-
notype), we postulated that the STAT5 phosphorylation pathway might be altered in diseased 
NK	cells.		STAT5	is	a	member	of	the	STAT	family	of	proteins,	which	signal	via	the	JAK/STAT	
pathway.	 	 STAT5	 is	 central	 to	modulation	 of	 the	 biological	 response	 to	 cytokines	 such	 as	 IL	
15,	and	STAT	phosphorylation	levels	were	recently	correlated	to	SLE	activity	in	humans	[109,	
110].  To determine whether NK cells from these organs have a differential capacity to phos-
phorylate	 STAT5,	 we	 used	 murine	 IL-15	 to	 stimulate	 fresh	 kidney	 lymphocytes	 and	 single	
cell	 suspensions	 from	spleen	and	BM	from	of	both	healthy	and	diseased	LPR	and	MPJ	mice.	
FACS analysis of BM and spleen showed no differences between the groups in the STAT5 ex-
pression	 levels	 after	 IL-15	 stimulation	 (Figure R.9). In contrast, kidney NK cells from dis-
eased	 LPR	 and	 MPJ	 mice	 showed	 higher	 pSTAT5	 phosphorylation	 levels	 than	 healthy	 MPJ	
and	prediseased	LPR	mice	after	IL-15	stimulation	(Figure R.9). Furthermore, kidney NK cells 
were seen to be able to phosphorylate more STAT5 than their spleen and BM counterparts.
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Figure R8 - Production of IFNγ after PMA/ionomycin stimulation of kidney infiltrating NK cells in 
healthy and diseased SLE-like mice
Ficoll-isolated kidney lymphocytes were incubated with PMA, ionomycin and BFA, and stained with anti-NKp46, 
-CD45,	-CD3,	-CD4,	-CD8,	-CD11b,	-CD27,	and	-IFNγ	mAb	(4	h).		 	 	A)	Percentages	of	CD45+NKp46+CD3-IFNγ+, 
CD45+NKp46-CD3+CD4+IFNγ+, and CD45+NKp46-CD3+CD8+IFNγ+	cells.		B)	Representative	flow	cytometric	density	
plots show the percentage of gated CD45+NKp46+CD3- and CD45+NKp46+CD3-CD11b+CD27-	cells	positive	for	IFNγ.	
C) Percentages of CD45+NKp46+CD3-CD11b+CD27-IFNγ+ and CD45+NKp46+CD3-CD27+IFNγ+ cells. D) Total MFI of 
CD45+NKp46+CD3-IFNγ+	cells.		Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	4	to	
6	mice/group	in	three	to	four	independent	experiments;	*p<0.05).
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Figure R9  - STAT5 phosphorylation of NK cells from healthy and diseased SLE-like mice after IL-15 
stimulation 
Fresh single cell suspensions of spleen, BM, and Ficoll-isolated kidney lymphocytes were activated with recombinant 
murine	IL-15	(15	min),	fixed,	permeabilized	and	stained	with	anti-NKp46,	-CD45,	-CD3,	and	-phospho-STAT5	mAb.	
A)	Representative	flow	cytometric	histograms	show	pSTAT5	expression	on	gated	CD45+	NK	cells	for	diseased	MPJ	
(blue	line),	diseased	LPR	(red	line),	healthy	MPJ	(green	line)	and	prediseased	LPR	mice	(red	line).		Isotype	control	
staining (grey line) is shown in each panel.  B) NK cells were gated for CD45+NKp46+CD3-	and	the	median	fluorescent	
intensities	were	calculated	for	total	pSTAT5	expression.	Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	
(mean	±	SD;	n	=	4/group	in	four	independent	experiments;	*p<0.05).
1.11  IL-15, but not IL-12, is increased in the kidneys of diseased SLE-like mice
 To elucidate possible mechanisms which might be implicated in the increase of mature 
NK	cells	in	the	kidneys	of	diseased	mice,	we	decided	to	analyze	the	levels	of	IL-15	and	IL-12,	
two cytokines, which as previously stated, are known for their importance in NK cell develop-
ment	and	activation.	The	levels	of	IL-15	were	measured	using	a	IL-15/IL-15	receptor	conjugated	
ELISA	kit,	as	it	has	been	reported	that	IL-15	in	vivo	is	mainly	secreted	both	in	mice	and	humans	
in	complex	with	its	unique	receptor,	IL-15Rα,	produced	by	either	dendritic	cells,	monocytes,	fi-
broblasts,	and/or	macrophages	[111,	112].	We	show	a	generalized	increase	in	the	levels	of	IL-15	
in	the	kidneys	of	diseased	SLE-like	mice	compared	to	their	controls,	but	not	of	IL-12	(Figure 
R.10).		Furthermore,	we	also	analyzed	the	levels	of	CXC3CL1,	a	chemokine	known	to	play	a	role	
in	NK	cell	migration	to	inflamed	organs	such	as	lung	and	skin	[37].	Via	ELISA	we	were	capable	
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Figure R10 – IL-15 but not IL-12 is increased in diseased SLE-like mice kidneys 
Total	levels	of	IL-15,		CXC3CL1,	and	IL-12	were	measured	from	the	supernatants	collected	from	kidney	tissue	ho-
mogenates.		The	final	concentration	of	cytokine	was	then	normalized	to	the	total	weight	of	each	organ.	A	representative	
experiment	of	each	ELISA	is	shown	(mean	±	SD;	n	=	2/group	in	two	independent	experiments).	Data	were	analyzed	
with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	4/group	in	four	independent	experiments;	***p<0,001,	
**p<0,01,	*p<0.05).
of	noticing	only	an	increase	in	the	levels	of	CXC3CL1	only	in	the	kidneys	of	prediseased	LPR	mice,	
but	not	in	the	other	groups,	which	showed	similar	expression	levels	of	CXC3CL1	(Figure R.10).
64
Part 2  NKG2D Ligand Expression the MRL mouse strain 
2.1 Rae-1 expression in MPJ, LPR and C57BL/6 mouse kidneys
	 NKG2D	ligand	involvement	in	SLE	pathogenesis,	particularly	in	the	glomerulonephritic	
process,	has	not	been	studied.		To	assess	whether	the	MRL	lupus-prone	genetic	background	causes	
NKG2D ligand upregulation and thus participates in glomerulonephritis onset, we tested NKG2D 
ligand	expression	in	MRL	mouse	kidney.		C57BL/6	(BL6)	mice	were	used	as	a	genotype-negative	
control strain, in which no ligand expression was anticipated.  We tested antibodies to various 
NKG2D	ligands,	including	H60	(not	expressed	in	BL6	mice),	Rae1,	and	MULT-1,	to	assess	their	
validity	 for	 immunohistochemistry	 [113,	114].	 	Only	 the	anti-Rae-1γ	antibody	AF1136	stained	
appropriately	[95].		In	our	experiments,	Rae	1γ	stained	clearly	in	the	glomeruli	of	3-month-old	
female	healthy	MPJ	and	diseased	LPR	mice,	but	not	in	equivalent	BL6	controls;	Rae-1γ	was	also	
stained	in	glomeruli	of	9-week-old	prediseased	LPR	and	1	year-old	diseased	MPJ	mice	(Figure 
R.11A).				Analysis	of	the	intensity	of	Rae-1γ	staining	showed	a	significantly	more	intense	staining	
in	the	glomeruli	of	diseased	LPR	and	MPJ	mice	than	in	their	healthy	counterparts	(Figure R.11B).
Figure R11 - Immunohistochemical analysis of Rae-1γ expression in healthy and diseased SLE-like 
mice
Analysis	of	Rae-1γ.		A)	Immunohistochemical	analysis	of	Rae-1γ	expression	in	kidney	tissue	cryosections	from	LPR,	
MPJ,	and	C57BL/6	mice	at	various	ages.		Specific	staining	(red)	is	observed	in	the	glomeruli	of	all	mice	of	the	MRL	
genotype,	whereas	staining	is	absent	in	C57BL/6	controls.		Representative	images	of	kidneys	from	five	mice	per	group.	
B)	Quantification	of	Rae-1γ	staining	in	MRL	mouse	glomeruli.		Data	were	analyzed	with	a	two-tailed,	unpaired	Stu-
dent’s	T	test	(mean	±	SD;	n	=	5/group;	**p<0.0001	*p<0.0025).
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2.2  Rae-1γ and MULT-1 expression are limited and specific to glomeruli of the 
MRL genotype
	 To	confirm	specific	Rae-1γ	expression	in	the	glomeruli	and	to	show	that	all	glomeruli	expressed	
this	NKG2D	ligand,	we	used	immunofluorescence	analysis	with	a	combination	of	antibodies	to	Rae-
1γ	and	to	synaptopodin,	a	marker	for	differentiated	glomerular	cells	[115,	116].		Rae-1γ		expression	
was	specific	to	synaptopodin-expressing	cells	and	all	glomeruli	were	Rae-1γ-positive	(Figure R.12).
Figure R12 - Representative immunofluorescent staining of Rae-1γ in a whole section from diseased 
LPR kidney
Cryosections	of	diseased	LPR	kidney	(10	μm)	were	co-stained	with	rabbit	anti-mouse	synaptopodin	(green)	and	goat	
anti-mouse	Rae-1γ	antibody	(red),	followed	by	appropriate	Alexa-conjugated	secondary	antibodies	and	DAPI	(blue).	
All	synaptopodin-positive	cells	corresponded	to	Rae-1γ-positive	cells,	indicating	glomerulus-specific	expression	of	this	
NKG2D ligand.  Negative controls using secondary antibody alone are not shown.
	 We	 evaluated	 expression	 of	 the	 other	 NKG2D	 ligand	 families	 on	 the	 MRL	 back-
ground.	 	 Using	 an	 anti-MULT-1	 antibody	 of	 known	 efficiency	 in	 immunofluorescence	
analysis,	 we	 tested	 kidney	 sections	 from	 MRL	 and	 BL6	 mice	 [99].	 	 Confocal	 analy-
sis	 of	 cryosections	 showed	 strong	 glomerulus-specific	 MULT-1	 expression	 in	 MRL	 but	
not	 BL6	 mice	 (Figure R.13). No anti-H60 antibodies tested showed positive staining.
Figure R13 - Confocal analysis of synaptopo-
din and MULT-1 expression in C57BL/6 and 
diseased LPR kidney sections 
Kidney cryosections  were stained with rabbit anti-
mouse	synaptopodin	(red)	and	anti-rat	MULT-1	(green)	
followed by appropriate secondary antibodies and 
DAPI	 (blue).	 	MULT-1	 expression	was	 absent	 in	 the	
C57BL/6	strain.
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	 To	 evaluate	whether	Rae-1γ	 is	 commonly	 expressed	 in	glomeruli	 of	 other	mice	prone	
to	 SLE-like	 disease	 and	 not	 in	 healthy	 strains,	 we	 used	 immunohistochemical	 analysis	 of	
Rae-1γ	 in	 kidney	 sections	 of	 diseased	 NZBxNZW(F1)	 and	 healthy	 3-month-old	 BALB/c	
mice.	 	 NZBxNZW(F1)	 is	 a	 SLE-like	 murine	 model	 whose	 lupus	 susceptibility	 is	 contribut-
ed	 by	 both	 the	NZB	 and	NZW	genomes.	These	mice	were	 positive	 for	Rae-1γ	 expression	 in	
glomeruli,	 while	 no	 Rae-1γ	 was	 observed	 in	 the	 glomeruli	 of	 BALB/c	 mice	 (Figure R.14).
Figure R14 - Representative immunohistochemical staining of Rae-1γ in glomeruli of NZBxNZW(F1) 
and BALB/c mice.
Rae-1γ	(red)	staining	shown	in	the	glomeruli	of	diseased	NZBxNZW(F1)	mice,	while	hematoxylin	counterstain	(blue)	
shows	cell	nuclei.		No	Rae-1γ	staining	was	observed	in	BALB/c	mice.		
2.3  NKp46 reactivity in MRL mouse tissues
	 Study	of	NK	cell	 infiltration	 in	 the	MRL	mouse	model	 required	a	 functional	antibody	
for	 immunohistochemical	 studies,	 as	 MRL	 mice	 are	 NK1.1-deficient	 and	 no	 NK	 cell-posi-
tive immunohistochemical marker has been reported to date for this model.  Previous studies 
showed	NK	 cell	 staining	 in	 BL6	mice	 using	 the	 4D11	 (anti-Ly-49G2)	mAb	 [117,	 118].	 	We	
nonetheless	detected	no	positive	 staining	with	 this	mAb	 in	MRL	spleen	 sections	 (not	 shown).	
We thus tested antibodies to other NK cell markers, and found that the anti-CD335 (NKp46) 
antibody	(AF2225)	stained	spleen	sections	of	BL6	and	MRL	mice	 (Figure R.15).	This	 is	first	
antibody	 reported	 for	 immunohistochemical	 identification	 of	 NK	 cells	 in	 the	 MRL	 model.
Figure R15 - Representative immunohisto-
chemical staining of NKp46 in C57BL/6 and 
MRL spleen sections.  
Red	membrane	staining	shows	NK	cells;	blue	counter-
stain (hematoxylin) shows cell nuclei.  Negative con-
trols not shown.
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2.4  NKp46, CD4 and CD8 infiltration in MRL and BL6 mouse glomeruli
 To ascertain whether NKp46+, CD4+ and CD8+	 cell	 infiltration	 correlates	 with	 glo-
merular	 infiltrates,	 we	 used	 immunohistochemical	 techniques	 to	 analyze	 the	 percentage	 of	
glomeruli	 that	 showed	NK,	CD4	 or	 CD8	 cell	 infiltration.	 	 Diseased	 LPR	mice	 showed	 high-
er levels of NKp46+, CD4+ and CD8+	 cell	 infiltration	 in	 glomeruli	 than	 all	 other	 mouse	
groups.	 	 Glomeruli	 of	 diseased	 MPJ	 and	 prediseased	 LPR	 mice	 also	 showed	 significant-
ly more NKp46+, CD4+ and CD8+	 cell	 infiltrates	 than	 healthy	 MPJ	 mice	 (Figure R.16).
Figure R16 - Quantification of NKp46, CD4, and CD8 infiltrates in glomeruli.
Representative	images	of	immunohistochemical	staining	of	NK	(NKp46),	CD4	(CD4)	and	CD8	(CD8)	cells	in	kidney	
tissue	cryosections	from	MPJ,	LPR,	and	C57BL/6	mice	at	various	ages.		Positive	staining	inside	glomeruli	(black	ar-
rows).		B)	Quantification	of	the	percentage	of	glomeruli	with	cell	infiltrates	per	field	(x100).		Data	were	analyzed	with	
a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	5/group;	25	kidney	sections/mouse,	*p<0.001,	**p<0.0001).
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2.5  NKG2D ligand expression in kidneys of SLE patients with active disease
	 To	ascertain	if	NKG2D	ligands	were	also	present	in	the	kidneys	of	diseased	SLE	patients,	
we	checked	via	immunohistochemistry,	for	the	presence	of	the	NKG2D	ligands	MICA	and	ULBP1	
in	six	patients	with	active	SLE	with	diagnosed	Stage	III	or	Stage	IV	lupus	nephritis.		Our	analysis	
revealed	only	a	slight	staining	of	ULBP1	in	one	patient	with	Stage	IV	lupus	nephritis	(Figure R.17). 
Figure R17 – Expression of NKG2D ligands in SLE patients with active disease.
Representative	images	of	immunohistochemical	staining	of	MICA	or	ULBP1	in	kidney	tissue	formalin-fixed	sections	
from	patients	with	active	SLE	or	healthy	cohorts.		Staining	was	only	noticed	in	patients	with	active	SLE	and	not	healthy	
controls. Negative control antibody stains are shown for each staining in each group. 
 However four out of the six patients tested showed diffused positive staining for 
MICA in both in glomerular and peritubular endothelium (Figure R.17 and Table R.1).  No 
staining	 for	 either	 MICA	 or	 ULBP1	 was	 had	 in	 control	 kidneys	 which	 were	 taken	 from	
healthy	 patient	 biopsies.	 	These	findings	 allow	us	 to	 postulate	 that	NKG2D	 ligands	might	 in-
deed	 be	 upregulated	 in	 patients	 with	 active	 SLE,	 even	 though	 a	 more	 thorough	 investiga-
tion with more patients and a larger panel of NKG2D ligand antibodies must be performed. 
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Table R.1 – List of patients with active SLE and relative staining intensity for ULBP1 or MICA
Pa#e%t	   Type	  of	  Nephropathy	   ULBP1	   MICA	  
1	   Stage	  IV	  (Global-­‐Chronic)	   -­‐	   ++	  
2	   Stage	  III	  (Acute/Chronic)	   -­‐	   -­‐	  
3	   Stage	  IV	  (Segmentated-­‐Acute/
Chronic)	  
-­‐	   -­‐	  
4	   Stage	  IV	  (Global-­‐Acute)	   -­‐	   +	  
5	   Stage	  IV	  (Global-­‐Acute)	   +	   +++	  
6	   Stage	  III	  (Acute)	   -­‐	   ++	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Part 3  Study of NK cell maturation in sustained Rae-1 expressing mouse 
models
3.1 Systemic and local Rae-1ε expressing mouse models
	 To	determine	 if	 high-levels	 of	 constitutive	Rae-1	 expression,	 as	 seen	 in	 the	 glomeruli	
of	diseased	SLE-like	mice	of	 the	MRL	genotype,	could	alter	 the	maturation	state	of	NK	cells,	
we	used	two	mice	models	which	constitutively	express	Rae-1ε.		One	of	these	transgenic	models	
expresses	high	levels	of	Rae-1ε	systemically,	via	its	control	under	the	chicken	β-actin	gene	and	
cytomegalovirus enhancer which is active in all tissues (FVB-187) (Figure R.18A). The second 
model,	expresses	Rae-1ε	under	the	control	of	a	human	involucrin	gene	promoter	active	only	in	
Figure R18 - Transgenic Rae-1ε protein expression from an epithelium-specific or globally active 
promotor
Diagram	showing	Rae-1ε	expression	(red)	either	in	FVB-187	(a)	or	FVB-121	(b)	mice.		C)	Factors	in	the	epidermis	can	
modulate	NK	cells	present	in	skin	draining	lymph	nodes.			Epidermal	factors,	such	as	the	increased	levels	of	Rae-1ε	in	
the epidermis in FVB-121 mice, can modulate NK cell responses either directly or indirectly.  Direct interaction with 
the epidermis occurs via either circulating NK cells from the blood stream, or dermis resident NK cells.  These cells can 
either interact with antigen presenting cells (APC), also located in the dermis.  Indirect modulation can occur if circulat-
ing NK cells which are located in the skin draining lymph nodes make contact with APCs in situ. 
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squamous epithelium (FVB-121)[119] (Figure R.18B). Using these two models, we checked if 
constitutive	Rae-1	expression	could	modulate	the	levels	of	the	CD11bCD27	NK	cell	subsets.		See-
ing	as	how	the	FVB-187	mice	constitutively	express	Rae-1ε,	we	decided	to	specifically	analyze	
peripheral	NK	cells	present	in	the	spleen.		In	FVB-121	mice,	as	Rae-1ε	expression	is	limited	only	
to the epidermis, we analyzed NK cells from skin draining lymph nodes, as NK cells present in 
these	lymph	nodes	would	be	capable	of	interacting	with	the	Rae-1ε	present	in	the	epidermis	either	
directly, via circulating NK cells, or indirectly, via the interaction these NK cells could have with 
other lymphocyte groups, such as antigen presenting cells (APC) (Figure R.18C) [120-122] . 
3.2 Systemic Rae-1 expression correlates with higher levels of CD11bHigh cells
 An initial analysis into the general expression levels of CD11b, showed a substantial 
increase in the MFI of CD11b in the NK cell compartment in both the spleen and skin drain-
ing lymph nodes of FVB-187 mice compared to their WT littermates (Figure R.19D). No 
differences in the MFI of CD11b in NK cells was noted in FVB-121 mice compared to their 
WT littermates in the skin draining lymph nodes (Figure R.19C).  However, the analy-
sis	 of	 the	CD11bCD27	 subsets	 showed	 a	 significant	 increase	 in	 the	 percent	 of	CD11bHighCD-
27Low and a tendency in the reduction of CD11bLowCD27High cells in NK cells from skin drain-
ing lymph nodes of FVB-121 mice compared to WT (Figure R.19A). No differences were 
noted in the CD11bCD27 subsets of FVB-187 mice compared to WT mice (Figure R.19B). 
Figure R19 - Analysis of CD11b and CD27 
subsets of  NK cells from mice expressing 
systemic levels of Rae-1e
A,B) Freshly isolated mouse lymphocytes from ei-
ther skin draining lymph nodes of FVB and FVB-
121 mice (a) or spleens of FVB and FVB-187 mice 
(b) were stained with anti-NKp46 and -CD3 mAb 
and analyzed for CD11b and CD27 expression. 
C,D)	The	median	fluorescence	intensity	of	CD11b	
in NK cells was analyzed for both FVB and FVB-
121 (c) mice and FVB and FVB-187 (d) mice. 
Data were analyzed with a two-tailed, unpaired 
Student’s	T	test	(mean	±	SD;	n	=	3	to	5	mice/group	
in	two	independent	experiments;	*p<0.05).
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3.3 Systemic Rae-1 expression correlates with higher IFN-γ production
 NK cells from skin draining lymph nodes of FVB-121 and spleens of FVB-187 mice were 
also	analyzed	for	IFN-γ-	production	after	stimulation	with	PMA	and	ionomycin.	Constitutive	and	
localized	Rae-1ε	expression	was	seen	to	correlate	with	increased	levels	of	IFN-γ	producing	NK	
cells in FVB-121 mice (Figure R.20). These results indicate that constitutive-localized expres-
sion	of	Rae-1	expression	is	capable	of	altering	NK	cell	maturation	and	IFN-γ	secreting	capacities.
Figure R20 - Production of IFNγ after PMA/
ionomycin stimulation of  NK cells from mice 
expressing systemic levels of Rae-1e
Lymphocytes	isolated	either	from	spleen	or	skin	draining	
lymph nodes were stimulated with PMA, ionomycin and 
BFA, and stained with anti-NKp46, -CD45, -CD3, and 
-IFNγ	mAb	 (4	 h).	 	 	A,B)	 Percentages	 of	NKp46+CD3-
IFNγ+ cells were calculated from skin draining lymph 
nodes from FVB and 121 mice (a) and splenocytes from 
FVB and 187 mice (b) Data were analyzed with a two-
tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	3	to	5	
mice/group	in	two	independent	experiments;	*p<0.05).
73
Part 4 Role of p85β in NK cell signaling
4.1 p85β is expressed in murine NK cells and does not influence the commitment or 
cellularity of NK cells
	 In	 order	 to	 define	 if	 the	 PI3K-p85β	 subunit	 was	 expressed	 in	 murine	 NK	 cells,	
we	 analyzed	 via	 qRT-PCR	 the	 levels	 of	 the	 p85β	 and	 of	 p85α	 subunits	 in	 six	 day	 IL-2	 ac-
tivated	NK	cells	 isolated	 from	C57BL/6	mice.	 p85β	was	detected	 to	 the	 same	extent	 as	 p85α	
in NK cells (Figure R.21 A).	 To	 define	 the	 possible	 role	 of	 p85β	 in	 early	NK	 cell	 develop-
ment, we analyzed NK cell numbers both in bone marrow and in spleen.  Both the percent-
ages and the absolute numbers of NKp46+CD3- cells were found not to vary in neither BM 
or	 spleen	 of	 p85β-/-	mice	 compared	 to	 their	 p85β+/+ (WT) littermates (Figure R.21 D,E,F,G).
Figure R21 – Phenotypic 
analysis of NK cell cellularity in
  p85β deficient mice 
A)	Total	RNA	was	extracted	from	spleen	de-
rived	six	day	IL-2	activated	NK	cells	from	
C57BL/6	mice.	Expression	of	the	p85α	and	
p85β	 mRNA	 was	 analyzed	 by	 qRT-PCR.	
Normalized	 quantities	 to	 β-actin	 (mean	
2-DCt)	of	p85α	and	p85β	mRNA	are	shown.	
B,C) Absolute numbers of spleen (a) and 
BM (b) cells were calculated from both 
p85β-/- and WT mice.  D,E,F,G) Percent-
ages and absolute numbers of NKp46+CD3- 
cells were calculated in both spleen (d, f) 
and BM (e,g). Data were analyzed with a 
two-tailed,	unpaired	Student’s	T	test	(mean	
±	SD;	n	=	8	mice/group	 in	 three	 indepen-
dent experiments).
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	 As	 previously	 stated,	 NK	 cell	 development	 can	 be	 defined	 as	 a	 five-	 or	 six-
step process, based on the expression pattern of cell surface markers [9, 29].  The matu-
rity of NK cells can be determined via the expression of various cell markers on its sur-
face, such as CD122, NKG2D, NK1.1, CD49b, CD11b, CD43, CD2, and CD11a. Gated 
NKp46+CD3-	 cells	were	 analyzed	 for	 expression	 of	 these	markers.	 	The	 deletion	 of	 the	 p85β	
subunit did not affect the expression of any of the aforementioned markers (Figure R.22).
Figure R22 – Analysis of developmental NK markers
Expression	 of	 developmental	markers	 in	 p85β	 -/-	NK	 cells	 in	 spleen	 and	 bone	marrow.	 	Representative	 histograms	
for	each	marker	are	shown.	 	Gates	were	set	using	unstained	or	nonspecific	 isotype	mAb	controls	 (not	depicted)	on	
NKp46+CD3-	cells.	Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	7-8	mice/group	in	
three independent experiments).
	 An	expression	profile	of	the	activating	and	inhibitory	Ly49	receptor	repertoire	indicated	
that	the	expression	levels	of	the	Ly49	A,	C,	D,	F,	G,	or	I	receptors	on	NK	cells	were	also	compa-
rable	between	p85β-/- and WT mice (Figure R.22).
 NK cell maturation, as previously stated can be further subdivided into another four-
stage process, dependent on CD27 and CD11b expression [105]. No differences were seen 
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between	 the	 proportion	of	 the	 various	CD11bCD27	 subsets	 between	 the	 p85β-/- and WT mice 
(Figure R.23).
Figure R23 p85β deficiency does not alter CD11bCD27 subsets
Freshly isolated mouse splenocytes and BM cells were stained with anti-NKp46 and -CD3 mAb and analyzed for CD11b 
and CD27 expression. Percentages were calculated of CD11bLowCD27High, CD11bHighCD27High, and CD11bHighCD27Low 
cells	for	splenocytes	and	BM	cells.	Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	6	
mice/group	in	three	independent	experiments)
	 In	 order	 to	 discard	 the	possibility	 of	 p85β	being	 implicated	 in	 the	 initial	 commitment	
of NK cells, we decided to look at the generation of NK precursor cells in the BM. NK cell 
differentiation from NKPs is a complicated process that begins in the BM with the generation 
of NKP cells, which are CD122+Lin-CD49b-NK1.1-.  These cells then follow a developmental 
pattern that gives rise to immature NK (iNK) cells in which they begin to express some but 
not	 all	 NK-specific	 developmental	 markers:	 CD122+Lin-CD49b-NK1.1-	 (Stage	 1	 -	 NKP)	 →	
CD122+Lin-NK1.1+CD49b-	 (Stage	 2)	 →	 CD122+Lin-NK1.1+CD49b+ (Stage 3) [1, 31, 105].
Figure R24 p85β deficiency does not alter NKP 
or iNK development
A) Absolute numbers were calculated of total Stage1, 
2, and 3 iNK cells. Data were analyzed with a two-
tailed,	 unpaired	 Student’s	 T	 test	 (mean	 ±	 SD;	 n	 =	 6	
mice/group	 in	 three	 independent	 experiments)	 B)	
Representative	flow	cytometric	density	plots	show	the	
proportion of CD122+Lin- cells.  Plots show propor-
tions of Stage 1 (CD122+Lin-NK1.1-CD49b-), Stage 2 
(CD122+Lin-NK1.1+CD49b-) and Stage 3 (CD122+Lin-
NK1.1+CD49b+) iNK cell groups in bone marrow
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Analysis of the total number of NKP and iNK cells showed no differ-
ences	 between	 p85β-/- mice and their WT counterparts (Figure R.24).
4.2 p85β does not influence NK cell apoptosis or death
	 In	order	to	ascertain	if	NK	cells	p85β	deficiency	could	be	implicated	in	NK	cell	death	
or apoptosis, fresh and 6 day activated BM and spleen NK cells were stained  with 7AAD and 
Annexin V.  No differences between the percent of Annexin V+7AAD- and Annexin V+7AAD+ 
were	 seen	neither	 in	 fresh	or	 IL-2	 activated	NK	cells	between	 the	 two	groups	 (Figure R.25).
Figure R25 p85β deficiency does not alter NK cell death or apoptosis  
A,B,C)	Freshly	 isolated	 splenocytes	 (a),	bone	marrow	cells	 (b),	or	 six	day	 IL-2-activated	 spleen	NK	cells	 (c)	were	
stained with Annexin V and 7-AAD for apoptosis analysis. Gates were set on NKp46+CD3- cells.  Percentages of posi-
tive	cells	were	determined.	Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	6	mice/
group	in	three	independent	experiments).		D)	Representative	flow	cytometric	density	plot	shows	the	proportion	of	An-
nexin V+7AAD- and Annexin V +7AAD+	cells	of	six	day	IL-2-activated	spleen	cells.	
4.3 p85β deficiency does not alter IL-2-activated NK cell proliferation
	 To	 assess	 if	 p85β	 deficiency	 was	 implicated	 in	 NK	 cell	 proliferation,	 we	 per-
formed	 BrdU	 proliferation	 assays	 on	 six	 day	 IL-2-activated	 splenic	 NK	 cells.	 	 Splenic	 NK	
cells	were	cultured	 for	6	days	with	 IL-2,	 and	 then	pulsed	with	BrdU	No	differences	 in	prolif-
eration	 were	 noticed	 between	 p85β	 deficient	 mice	 and	 their	WT	 counterparts	 (Figure R.26).
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Figure R26 - p85β deficiency does not alter 
NK cell proliferation  
Six-day	 IL-2-activated	 splenic	 NK	 cells	 were	
pulsed	 with	 BrdU,	 and	 incubated	 at	 37°C	 for	 4	
hours.  NK cells were then stained and analyzed 
for NKp46+CD3- proliferation.  A representative 
histogram of one of two independent experiments 
is shown. Data were analyzed with a two-tailed, 
unpaired	Student’s	T	test	(mean	±	SD;	n	=	2	mice/
group in 2 independent experiments) 
4.4 p85β deficiency marginally increases NK cell CD107a degranulation but not 
conjugation
	 To	assess	whether	BM	and	spleen	NK	cells	in	a	SLE	environment	also	have	functional	
defects,	we	performed	conjugation	and	CD107a	degranulation	assays	using	6-day-cultured	IL-2-
activated	NK	cells	from	p85β-/- and WT mice.  Conjugation in short intervals was tested against 
Schneider	Cell	Line	2	drosophila	cells	(S2)	transfected	with	ICAM1	(S2-mICAM1)	or	ICAM1	
and	MULT-1	(S2-MULT-1/mICAM1)	and	 the	YAC-1	cell	 line.	 	 ICAM1	has	been	shown	to	be	
both	necessary	and	 sufficient	 for	 the	 correct	 conjugation	of	NK	cells	 in	humans,	 and	S2	cells	
have been already shown to be excellent target cells for NK cells after transfection with the ap-
propriate	ligands	[123].		p85β-/-  NK cells showed no impaired capacity to conjugate either S2-
Figure R27 p85β deficiency does not alter NK cell conjugation
Six-day	IL-2-activated	spleen	NK	cells	were	tested	in	a	four-point	conjugation	assay	against	S2-mICAM1	(4:1	target	
effector	 ratio)	 	 ,	 S2-MULT-1/mICAM1	 (4:1	 target	 effector	 ratio)	 and	YAC-1	 (2:1	 target:effector	 ratio).	 	Data	were	
analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	(mean	±	SD;	n	=	3	mice/group	in	three	independent	experiments)	
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mICAM1,	S2-MULT-1/mICAM1	or	YAC-1	cells	(Figure R.27). Furthermore, no the co-expres-
sion	 of	MULT-1	with	mICAM1	did	 not	 seem	 to	 alter	 the	 conjugation	 capacities	 of	NK	 cells.
 Degranulation	 of	 the	 lysosome-associated	 membrane	 protein-1	 CD107a	 (LAMP-1)	
is upregulated on the NK cell surface following stimulation with target cells able to induce a 
cytolytic response, and occurs after NK cells have successfully conjugated to their target cells. 
To	 determine	 whether	 or	 not	 p85β	 deficiency	 could	 be	 implicated	 in	 CD107a	 degranulation,	
6-day-cultured	 IL-2-activated	NK	cells	 from	p85b-/- and WT mice were stimulated against the 
YAC-1 (NKG2D ligand expressing) and CHO (which express a homologue of H2-Dd) tar-
get	 cells.	A	 tendency	 in	 the	 increase	 of	 CD107a	 degranulating	 p85β-/- NK cells after stimu-
lation with both CHO and YAC-1 cells was noted compared to WT NK cells (Figure R.28).
Figure R28  Analysis  of CD107a secretion in 
p85β deficient mice 
A,B)	Six-day	IL-15-activated	spleen	or	BM	NK	cells	
were tested against the CHO and YAC-1 target cell 
lines	at	a	2:1	 target:effector	 ratio	 in	a	4	h	CD107a	
degranulation	 assay.	 	 Representative	 stainings	 are	
shown (b); data were analyzed  with a two-tailed, 
unpaired	Student’s	T	test.
4.5 p85β deficiency augments NK cell cytotoxicity
	 In	order	 to	 evaluate	 if	p85β	deficiency	 influenced	NK	cell	 cytotoxicity,	we	performed	
NK	 cell	 cytotoxicity	 assays	 with	 6-day-cultured	 IL-2-activated	 NK	 cells.	 	As	 target	 cells	 we	
used	the	NKG2D	ligand	expressing	cell	line,	YAC-1,	and	S2	cells	transfected	with	the	MULT-
1	NKG2D	ligand	and	murine	 ICAM1	(S2-mICAM1/MULT-1).	 IL-2-activated	p85β-/- NK cells 
seemed to show marginally enhanced cytotoxicity towards both target cells compared to their WT 
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counterparts (Figure R.29).
Figure R29 IL-2-activated p85β-/- NK cell cytotoxicity is moderately increased
IL-2-activated	splenic	NK	cells	were	tested	against	PKH67	labeled	target	cells	at	the	indicated	effector/target	ratios.	
Cytotoxicity	was	tested	against	the	YAC-1	and	S2-MULT-1/mICAM1	cells.		Shown	are	the	means	of	three	independent	
experiments	for	S2-MULT-1/mICAM1	and	2	independent	experiments	for	YAC-1	(a,b)	,	and	two	representative	indi-
vidual	experiments	with	each	target	cell	(c-f).		Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test
4.6 p85β deficiency increases NKG2D activated cytokine generation 
	 NK	cells	are	known	producers	of	various	pro-inflammatory	cytokines,	of	which	one	of	the	
most	important	is	IFNγ.			Therefore,	we	tested	NKp46+CD3-	NK	cells	for	IFNγ	generation.		Six	day	
spleen	derived		IL-2	activated	NK	cells	were	stimulated	with	anti-NKG2D	and	anti-NK1.1	antibodies.	
mAb-stimulated	NK	cells	were	seen	to	produce	large	amounts	of	IFNγ	upon	stimulation,	yet	p85β-/- 
cells	showed	increased	IFNγ	production	when	stimulated	compared	to	WT	NK	cells.	(Figure R.30A).
 Via luminex, we also checked the levels of other typical NK cell cytokines. Albeit 
having performed only one experiment with two samples, we noticed an increase in the lev-
els	 of	 IP10,	 IL10,	 TNF-a,	 IL-6,	 and	 RANTES	 in	 p85β	 deficient	 IL-2	 –activated	 NK	 cells	
compared to WT cells after stimulation with both NK1.1 and NKG2D (Figure R.30B).
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Figure R30 IL-2-activated p85β-/- NK cell cytokine generation is increased
A)	2*105	 IL-2-activated	splenic	NKp46+CD3- cells per well were activated with plate-bound anti-NKG2D (A10) or 
anti-NK1.1	(PK136	mAbs)	and	the	supernatants	were	tested	for	IFN-γ	via	ELISA	(mean	±	SD;	n	=	5	mice/group	in	
5	independent	experiments;	**p<0.01).	Data	were	analyzed	with	a	two-tailed,	unpaired	Student’s	T	test	B)	2*105	IL-
2-activated splenic NKp46+CD3- cells per well were activated with plate-bound anti-NKG2D (A10) or anti-NK1.1 
(PK136	mAbs)	and	the	supernatants	were	tested	for	the	indicated	cytokines	and	chemokines	in	a	Luminex	assay.		(n	=	
2	mice/group	in	1	experiment).
4.7 p85β deficient NK cells show impaired NKG2D downregulation
	 Recent	 evidence	has	 suggested	 that	PI3K	kinases	might	play	a	 role	 in	 the	 internaliza-
tion of receptors which include the PI3K p85 binding motif [124].  To evaluate the possible ef-
fect	 p85β	 could	have	on	 the	 regulation	of	 the	NKG2D	activating	 receptor,	we	decided	 to	 test	
for NKG2D downregulation. This was achieved by stimulating freshly isolated NK cells with 
the NKG2D activating antibody (clone A10) at various time points, and then by analyzing cell 
surface expression of NKG2D with the use of the CX5 antibody which stains for another epitope 
of	NKG2D.	Our	analysis	show	a	decrease	in	the	internalization	of	the	NKG2D	receptor	in	p85β-/-
NK cells compared to WT NK cells (Figure R.31).  
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Figure R31 p85β deficiency correlates with defects in NKG2D receptor internalization 
p85β-/- and WT NK cells were stimulated with an activating NKG2D mAb (A10) for indicated time points and KIT 
receptor internalization was studied by staining the cells with PE-conjugated anti-NKG2D antibody (CX5) followed 
by	flow	cytometric	analysis.	 (mean	±	SD;	n	=	3	mice/group	in	 three	 independent	experiments;	*p<0,05)	Data	were	
analyzed	with	a	two-tailed,	unpaired	Student’s	T	test

Discussion
In order to be accepted as a model, a theory must seem superior to rival theories, but does not 
need– nor will it ever - explain all of the events it will encounter
Thomas S. Kuhn 
Science	may	be	described	as	the	art	of	systematic	over-simplification	—	the	art	of	discerning	
what we may with advantage omit.
Karl Popper
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Possible role of NK cells in SLE
	 Whereas	the	MRL	mouse	strain	has	long	been	used	to	study	SLE,	little	attention	has	been	
paid to the role of NK cells in this model.  To date, the only information on NK cells in the pe-
riphery	of	human	SLE	patients	indicates	reduced	expression	and	number	of	CD122+ NK cells, a 
reduction in total NK cell number and in their cytotoxicity [71, 72].  Proliferation, cytotoxicity and 
differentiation	defects	are	reported	for	NK	cells	derived	from	haematopoietic	BM	cells	from	SLE	
patients,	but	not	from	fresh	BM	samples	[71].		The	MRL/MpJlpr	is	of	great	use	to	the	study	of	SLE	
due	to	the	rapid	onset	of	SLE-like	symptoms,	but	its	accelerated	phenotype	is	due	mainly	to	the	re-
cessive autosomal mutation which alters the transcription of the Fas receptor [101].  Indeed, even 
though	this	model	mimics	many	aspects	found	in	SLE	patients	and	that	defective	Fas	signaling	
has	been	correlated	with	the	development	of	autoimmune	lymphoproliferative	syndrome	(ALPS),	
which	shares	many	symptoms	with	SLE,	the	extreme	autoimmune	manifestations	that	these	mice	
exhibit, such as the immense accumulation of double negative and B220+ T cells are neither typi-
cal	nor	common	in	all	SLE	patients	[125].		However,	it	is	known	that	the	lpr	mutation	by	itself	
is	not	capable	of	resulting	in	glomerular	nephritis,	and	that	Fas	sufficient	MRL/MpJ	mice	have	
background	genes	which	are	capable	of	promoting	and	developing	SLE-like	symptoms,	in	a	more	
“natural”,	 albeit	 slower	manner	 compared	 to	MRL/MpJlpr mice [101, 126].  Nonetheless, only 
the	MRL/MpJlpr	mouse	strain	has	been	slightly	used	to	study	the	role	of	NK	cells	in	SLE,	and	no	
information	to	date	has	been	published	regarding	the	role	of	NK	cells	in	diseased	MRL/MpJ	mice.
	 To	our	knowledge,	the	phenotype	of	NK	cells	in	a	SLE/SLE-like	environment	had	not	been	
extensively	characterized.		Here	we	confirm	previous	data	indicating	a	reduction	in	the	percentage	of	
NK	cells	in	diseased	LPR	mice	and	show	a	similar	reduction	in	diseased,	1-year-old	MPJ	mice,	indi-
cating	their	usefulness	for	the	study	of	NK	cells	in	SLE	[72].		Comparison	of	percentages	and	absolute	
numbers of NKp46+CD3-	cells	in	diseased	and	healthy	LPR	and	MPJ	mouse	BM	suggested	that	the	
reduction observed in the periphery in diseased mice is not due to defective NK cell production in BM
	 We	 analyzed	 cell	 surface	 expression	 of	 NK	 markers	 in	 SLE-like	 mouse	 BM	 and	
spleen	 to	 determine	 the	 influence	 of	 microenvironmental/organ-specific	 differences	 on	 NK	
cell phenotype.  NKp46+CD3- cells in diseased mouse spleen showed downregulation of ma-
ture NK cell markers, which was more notable than in BM.  There were no differences in 
BM	 CD11b,	 CD43,	 CD122	 or	 CD2	 expression	 levels	 between	 healthy	 and	 diseased	 MPJ	
and	LPR	mice.	 	 In	 diseased	mouse	 spleen,	NK	 cell	 surface	 levels	 of	CD43,	CD49b,	CD122,	
CD2	 and	 CD11b	 were	 significantly	 downregulated.	 	 We	 thus	 postulated	 that	 in	 diseased	
mice,	 the	 SLE-like	microenvironment	 already	 affects	NK	 cell	maturation	 in	BM,	 although	 to	
a much lesser extent than in spleen.  Several reports show a non-mature functional phenotype
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in	peripheral	NK	cells	from	SLE	patients	and	from	diseased	LPR	mice,	characterized	by	reduced	
CD122 expression and cytotoxicity [71, 76, 77].  We found that this non-mature functional phe-
notype correlates with decreased expression of various mature NK cell markers.  High CD11b, 
CD43, CD49b and CD122 levels are markers of functional, mature NK cells; their reduction 
in	 diseased	 LPR	 and	MPJ	 mice	 thus	 indicated	 a	 probable	 increase	 in	 less-mature	 NK	 cells.
 To	determine	whether	expression	of	these	defining	markers	for	NK	cell	maturation	de-
creased after acquisition of a fully mature state or if the NK cells suffered developmental defects, 
we analyzed NK cell precursor numbers in BM and in spleen.  This four-stage process is far better 
understood	in	mice	than	in	humans	(NK1.1,	a	defining	marker	for	NK	cell	development,	was	not	
considered	as	it	is	not	expressed	in	the	MRL	strain).		As	previously	stated,	NKP	cells	have	been	
found in various organs outside the BM, it is thought that they arise in BM, travel to other organs 
and develop fully in situ.  We thus proposed that in diseased mice, NK cells develop differently in 
spleen than in BM.  In accordance with our data, we found no differences in total NKP or iNK cell 
numbers in any of the four developmental stages in BM. In the spleen of diseased mice, we observed 
accumulation of iNK and NKP cells in Stages 1 2, and 3; this led us to postulate that NK cells do not 
develop correctly in diseased mouse periphery.  NK cells in diseased patients are thought to suffer 
impaired	maturation	and	differentiation,	and	indeed,	NK	cell	activation	and	maturation	is	influenced	
by microenvironmental factors such as the cytokine milieu or marrow stromal cells [77, 127, 128].
 These data correlated with our analysis of CD11bCD27 NK cell subsets in spleens from 
SLE-like	mice.		Accumulation	of	CD11bLowCD27High and a decrease in the percentage of CD11b-
HighCD27Low NK cells is further evidence that, in diseased mouse spleen, NK cells do not develop a 
completely mature phenotype. Furthermore, this increase in the CD11bLowCD27High could possibly 
mimic the CD56Bright	population	which	has	been	found	to	be	increased	in	SLE	patients	with	an	active	
disease, and which are known to represent the same immature NK cell subtype in humans [129, 130].
 To determine whether decreased expression of these mature NK cell markers cor-
related	with	 functional	 deficiencies,	we	performed	 conjugation	 and	CD107a	degranulation	 as-
says	using	6-day-cultured	 IL-15-activated	NK	cells	 from	BM	and	 spleen.	 	We	used	 the	YAC-
1 cell line for conjugation assays, as it expresses a variety of cell surface receptors involved 
in NK cell conjugation, including ICAM1, ICAM2, and CD48.  Preliminary data we collected 
showed	 that	 CHO	 and	RMA/S	 cells	 did	 not	 conjugate	well	 at	 short	 times	 (not	 shown).	 	The	
assays indicated no differences in the conjugation capacity of activated BM NK cells from dis-
eased	LPR	and	healthy	MPJ	mice.	 	Activated	spleen	NK	cells	 from	diseased	LPR	mice	none-
theless showed decreased ability to form target-effector cell conjugates at longer times; this 
defect could be due to the decrease in CD2-expressing NK cells in these mice, as the CD2 li-
gand CD48 has a decisive role in strengthening formation of NK cell conjugates [123].
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	 Studies	to	date	have	focused	on	measuring	the	cytotoxicity	of	NK	cells	from	SLE	patients	
and	SLE-like	murine	models.	 	 Since	CD107a	 degranulation	 correlates	with	NK	cell-mediated	
cytotoxicity, we used this assay as an alternative to measure NK cell cytotoxicity.  After stimula-
tion	with	various	target	cell	lines,	IL-15-activated	spleen	and	BM	NK	cells	from	diseased	LPR	
mice	had	 fewer	CD107a-expressing	cells	 than	healthy	MPJ	mice.	 	These	data	confirm	 reports	
of reduced NK cell cytotoxicity in spleen and peripheral blood, although here we used freshly-
extracted, activated BM NK cells directly in a cytotoxic assay [71, 72].  These data might slightly 
contradict	 a	previous	 study	 in	which	 IL-2-activated	human	NK	cells	 from	peripheral	blood	of	
patients	with	active	SLE	showed	no	differences	 in	degranulation	compared	to	healthy	controls	
[77]; these differences might be due to the use of distinct cytokines used for NK cell activation 
and/or	 target	 cell	 lines.	 	Another	 study	 showed	 reduced	cytotoxicity	of	human	haematopoietic	
stem cells differentiated in vitro to NK cells [71]; our results add to the data from this report, 
as	we	used	 IL-15-activated	NK	cells	extracted	directly	 from	BM.	 	The	CD107a	degranulation	
defect	 found	both	 in	BM	and	periphery	allows	us	 to	postulate	 that	 the	SLE	microenvironment	
in diseased mice is already able to reduce the cytotoxic capacity of mature NK cells in BM. 
Whereas cytometric analyses of NK cell surface expression markers appear to indicate that 
NK	cells	 from	diseased	mice	 show	 a	more	 pronounced	 “immature”	 phenotype	 in	 spleen	 than	
in	 BM,	BM	NK	 cells	might	 already	 be	 in	 a	 context	 that	 influences	 their	 functional	 capacity.	
 There is little information regarding the phenotypic and functional aspects of NK cells in 
SLE	target	organs.		To	date,	only	three	studies	have	shed	some	light	on	this	aspect.		Two	studies	
reported	that	the	phenotype	of	liver	and	lung	NK	cells	from	diseased	MRL/lpr	mice	was	more	
cytotoxic	 than	 that	of	healthy	MRL/MpJ	or	MRL/lpr	mice	 [131,	132].	 	 In	another,	PMA-	and	
ionomycin-stimulated	NK	cells	from	diseased	MRL/lpr	mice	produced	more	cytotoxic	granules	
compared	 to	prediseased	MRL/lpr	or	healthy	MRL/mpj	mice	 [72].	 	These	data	 imply	 that	 the	
phenotype of NK cells in target organs might be reversed compared to NK cells in the periph-
ery.	 	Our	 first	 step	was	 to	 analyze	 via	 flow	 cytometry	 the	 lymphocyte	 populations	 present	 in	
healthy	and	SLE-like	diseased	kidneys.	 	Our	analysis	revealed	an	 increase	 in	 the	 total	number	
of CD45 lymphocytes in diseased kidneys compared to their respective controls.  Furthermore, 
as has been already noted in other non-lymphoid organs, the percent of NK cells in healthy kid-
neys	accounts	for	around	≈10%	of	the	lymphocyte	population.	 	The	percent	of	NK	cells,	as	in	
the periphery, was seen to diminish in diseased kidneys compared to healthy ones, even though 
the	absolute	numbers	of	NK	cells	did	not	vary,	except	for	an	increase	in	the	diseased	LPR	mice.
 Our cytometric staining of the NK cells from lymphocytes derived from healthy and dis-
eased mouse kidneys showed that NK cells in diseased kidneys did not downregulate markers 
that were downregulated in BM and spleen.  Moreover, NK cells from diseased mice suffering 
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severe nephritic lupus had increased CD11b levels compared to healthy mice, suggesting a 
higher	 activation	 state	 of	NK	cells	 in	 inflamed	kidneys.	 	This	 increased	CD11b	 expression	 in	
diseased kidney NK cells correlated with an increase in the percentage of CD11bHighCD27Low 
cells and a decrease in the percentage of CD11bLowCD27High, another indication of a more ma-
ture phenotype in NK cells in nephritic kidneys compared to peripheral NK cells.  This CD11b 
increase	 correlated	with	 a	 larger	 percentage	 of	 kidney-infiltrating	NK	 cells,	which	 respond	 to	
PMA	and	 ionomycin	 stimulation	 and	 thus	produce	higher	 IFN-γ	 levels.	 	We	 found	 significant	
differences	 between	 the	 percentage	 of	 IFN-γ-producing	 cells	 in	 diseased	 and	 healthy	 mice	
specifically	 in	 the	 CD11bHighCD27Low	 population,	 indicating	 that	 these	 more	 mature,	 infiltrat-
ing	NK	cells	 are	 responsible	 for	 the	 increased	 IFN-γ	production.	 	While	 the	 literature	 to	 date	
seems to support the idea that CD27High	 cells	 are	 the	main	 effector	 cells	 and	 IFN-γ	 producers	
[36],	 it	might	be	possible	 that	 these	kidney	 infiltrating	NK	cells	are	part	of	a	distinct	NK	cell	
subtype.	 These	 kidney	 infiltrating	 NK	 cells	 might	 have	 a	 more	 pronounced	 “inflammatory-
helper”	role,	rather	than	acting	as	direct	effectors	of	cytotoxicity.		Unfortunately,	since	we	were	
incapable	of	 isolating	and	culturing	kidney	 infiltrating	NK	cells,	we	were	not	 capable	of	 test-
ing the cytotoxic capacities of these CD11bHighCD27Low kidney cells against NK cell targets. 
 STAT5 plays a crucial part in NK cell signaling, given its role in the development and 
survival of NK cells, and in transducing and activating a myriad of biological processes after NK 
cell	stimulation	with	cytokines	such	as	IL-2,	IL-15,	and	IL-21	[110,	133].		To	determine	whether	
the	phenotypic	differences	 in	 the	various	organs	correlated	with	deficient	STAT5	phosphoryla-
tion, we incubated freshly isolated NK cells (mature CD45+NKp46+CD3-	cells)	with	IL-15.		The	
results	showed	no	significant	differences		between	the	phosphorylation	levels	of	STAT5	in	NK	
cells	from	spleen	or	BM.		On	the	other	hand,	NK	cells	from	diseased	kidneys	were	seen	to	signifi-
cantly phosphorylate more STAT5 compared to NK cells from healthy and prediseased kidneys. 
Moreover, the fact that kidney NK cells phosphorylated more STAT5 in general compared to NK 
cells	 from	BM	or	spleen	suggests	 that	kidney	resident/infiltrating	NK	cells	have	a	generalized	
more	active/mature	state,	which	is	hard	to	explain	only	based	on	the	CD11b	and	CD27	subsets.
 In order to identify possible mechanisms that could be implicated in the differences in 
NK cell maturation which we report between diseased and healthy kidneys, we analyzed the 
levels	of	IL-15	and	IL-12	in	the	kidneys	of	all	four	mouse	groups.		Our	analysis	revealed	what	
seemed	to	be	a	correlation	between	higher	levels	of	IL-15	in	diseased	kidneys	compared	to	healthy	
kidneys.	 	 IL-15,	being	one	of	 the	main	players	 in	NK	cell	development,	could	 thus	be	one	of	
the likely candidates implicated in the more mature phenotype which we report in the kidneys 
of	 diseased	 SLE-like	 mice.	 	 Furthermore,	 the	 increase	 of	 IL-12	 in	 prediseased	 LPR	 kidneys
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might	mimic	data	found	in	patients,	in	which	increases	of	serum	IL-12	was	found	right	before	dis-
ease	flares	[134].	Thus	IL-12	levels	might	increase	and	participate	in	NK	cell	activation	in	the	stag-
es which immediately proceed an active disease state in diseased kidneys.  Similarly, the increase 
of	CX3CL1	in	the	kidneys	of	prediseased	LPR	mice,	might	instead	be	the	cause	for	the	infiltration,	
and	thus	higher	numbers	of	NK	cells,	typical	only	to	the	LPR,	but	not	MPJ	SLE-like	model.		A	
possible	explanation	for	our	detected	increase	of	CX3CL1	and	IL-12	in	prediseased	LPR	kidneys	
but	not	healthy	MPJ	kidneys	would	probably	be	due	to	the	time	point	in	question,	seeing	as	how	
healthy	MPJ	kidneys	would	still	be	months	away	from	developing	any	sort	of	inflammatory	state.
	 We	 here	 report	 Rae1	 and	 MULT-1	 expression	 specifically	 in	 glomeruli	 of	 the	 MRL	
mouse strain.  As this strain develops lupus-like disease independently of the Fas muta-
tion	 in	 the	MRL/MpJlpr mice, it appears that the genetic background of these mice predispos-
es	 to	 late-onset	 SLE-like	 symptoms.	 	 In	 kidney,	 expression	 of	 these	 ligands	 is	 specific	 to	 the	
glomeruli,	which	 allows	us	 to	postulate	 that	 this	predisposed	SLE	background	 is	 the	 cause	of	
NKG2D	ligand	expression,	not	present	in	C57BL/6	or	BALB/c	control	strains.		We	also	found	
a	 correlation	 between	 heightened	 Rae-1	 expression	 in	 the	 glomeruli	 of	 diseased	 mice	 com-
pared to healthy controls.  The glomeruli of mice in an active disease state might thus be sub-
ject	 to	 a	 broader	 “stress-induced”	 environment,	 which	 could	 be	 responsible	 for	 increased	
expression	 of	 this	 NKG2D	 ligand.	We	 also	 report	 Rae-1	 expression	 in	 the	 glomeruli	 of	 dis-
eased	 NZBxNZW(F1)	 mice,	 another	 glomerulonephritis	 model.	 	 This	 confirms	 expression	
of	 detectable	 NKG2D	 ligand	 levels	 in	 glomerulonephritic	 kidneys	 of	 three	 SLE-like	models.	
	 To	see	if	the	same	pattern	of	NKG2D	ligand	expression	was	also	seen	in	SLE	patients,	
we analyzed kidney biopsies of patients with an active lupus nephritic state for the expression 
of	 the	 human	 NKG2D	 ligands	MICA	 and	 ULBP1.	 Our	 immunohistochemical	 stainings	 only	
showed	 one	 patient	 which	 showed	 a	 very	 light	 staining	 for	 ULBP1,	 but	 four	 patients	 which	
showed mild to intense staining of MICA in the glomerular and peritubular endothelium.  Even 
though	we	were	not	capable	of	reproducing	such	a	specific	glomerular	stain	of	NKG2D	ligands,	
such	as	what	was	noted	 in	our	SLE-like	mouse	models,	 the	pattern	of	expression	of	MICA	in	
patients	with	active	SLE	resembles	what	has	been	previously	reported	in	kidney	sections	from	
patients	 suffering	 from	Wegener’s	 granulomatosis	 [135].	Wegener’s	 granulomatosis	 is	 an	 in-
flammatory	disease	of	unknown	origin,	and	whose	most	 life-threatening	symptom	is	 its	necro-
tizing	 glomerulonephritis.	 	 Patients	with	 an	 active	 state	 of	Wegener’s	 granulomatosis	 showed	
both increased levels circulating MICA+ cells in the blood and positive expression of MICA in 
both the glomerular and peritubular epithelium in the kidneys [135].  Thus, the expression of 
MICA,	even	though	not	glomerular	specific,	seems	to	be	specifically	upregulated	during	the	active	
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stages	 of	 inflammatory-autoimmune	 kidney	 manifestations.	 	 This	 together	 with	 re-
ports	 that	 link	 MICA	 polymorphism	 to	 the	 pathogenesis	 of	 SLE	 via	 the	 possible	 mod-
ulation of CD4+,	 NK,	 and/or	 monocytes	 is	 an	 interesting	 link	 to	 the	 possible	 ef-
fects	 of	 MICA	 expression	 in	 the	 kidneys	 of	 patients	 with	 active	 SLE	 [78,	 136,	 137].
	 Based	on	the	analysis	of	kidney	infiltration	levels	of	NKG2D-expressing	cells	(NK,	CD4	
and CD8 cells), we report the participation of these cytotoxic cells in glomerulonephritis.  It has 
already been reported that NK, and other NKG2D-expressing cells can accumulate in tumors 
expressing NKG2D ligands [138, 139]. Using immunohistochemical techniques, we observed sig-
nificantly	higher	numbers	of	glomeruli	with	cytotoxic	cellular	infiltrates	in	diseased	mouse	kidneys	
compared to pre-diseased and healthy controls.  This result was not reproduced in cytometric anal-
ysis, which only indicated an increase in total numbers of CD4+, CD8+ and NK cells only in diseased 
LPR	mouse	kidney.		During	glomerulonephritis,	NK	cells	might	thus	have	a	qualitative	rather	than	
a quantitative role, as there appears to be no notable difference in total NK cell numbers between 
diseased	MPJ	mice	and	the	control	groups.		Notwithstanding,	this	result	contrasts	with	a	previous	
study in which larger numbers of NK cells were found in kidneys of pre-diseased compared to dis-
eased	LPR	mice	[72].		Whereas	the	discrepancies	with	our	results	could	be	attributed	to	the	distinct	
techniques	and	cell	markers	used	for	NK	cell	screening	(we	use	NKp46,	CD45,	and	a	live/dead	
cell discrimination marker), the previous report was limited to total cell count in the whole kidney, 
and did not consider the percentage of NK cells that participate in the glomerulonephritic process. 
Regardless	of	whether	or	not	total	NK	cell	numbers	increase	in	diseased	or	pre-diseased	kidneys,	
our	data	show	a	correlation	between	infiltration	of	mouse	glomeruli	and	an	active	disease	state.
 In order to evaluate if the increased glomerular expression of NKG2D ligands could be 
a	possible	cause	 for	 the	more	NK	cell	phenotypes	we	noticed	 in	 the	kidney	of	diseased	SLE-
like mice, we used the FVB-121 and FVB-187 mouse models, which constitutively express an 
isoform	of	the	Rae-1	ligand	(Rae-1ε)	either	locally	in	the	epidermis,	or	systemically.		While	the	
analysis	of	the	specific	effects	of	constitutive	Rae-1	expression	in	the	FVB-187	model	is	chal-
lenging,	due	to	the	fact	that	Rae-1	is	expressed	systemically	(even	on	the	NK	cells	themselves)	
[95],	the	FVB-121	model	serves	as	a	more	localized	“physiological”	form	of	increased	NKG2D	
ligand expression, which we believe more accurately mimics what occurs in the kidneys of the 
SLE-like	 mice	 (localized	 expression	 of	 Rae-1).	 	 Veritably,	 the	 localized	 expression	 of	 Rae-1	
correlated with higher levels of mature CD11bHighCD27Low	NK	 cells	 and	with	 an	NK	 specific	
higher	 IFN-γ	production	compared	 to	 the	FVB-187	mice,	which	 showed	 the	 same	 tendencies,	
but	to	a	lesser	extent.	 	The	maturation	profile	of	NK	cells	in	the	skin	draining	lymph	nodes	of	
FVB-121	mice	thus	closely	resembles	that	of	kidney	infiltrating	NK	cells	in	diseased	SLE-like	
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mice.	 	 Thus,	 if	 Rae-1,	 or	 NKG2D	 ligand	 expression	 in	 general	 is	 capable	 of	 influenc-
ing	 NK	 cell	 maturation	 and/or	 functional	 capacities,	 it	 still	 remains	 to	 be	 discovered	
what threshold of expression these ligands must have in order to exert this effect.  In-
deed,	 if	 healthy,	 SLE-prone	mice	 already	 express	 low	 levels	 of	Rae-1,	what	 is	 the	Rae-1	 ex-
pression threshold that has to be passed in order for it to be capable of regulating NK cells? 
Figure D1 Model for altered NK cell phenotype during active SLE
In	this	model,	we	propose	that	the	more	activated	NK	cell	phenotype	in	the	kidneys	of	mice	who	are	in	an	active	SLE-
like	disease	state	is	possibly	due	to	both	the	increase	expression	levels	of	Rae-1	in	the	glomeruli	and	of	total	IL-15R/
IL-15	levels	in	the	kidneys.		These	two	factors,	could	explain	the	increase	in	the	levels	of	mature	NK	cells,	and	in	their	
increased	secretion	of	IFN-γ.		In	the	spleen,	yet	unknown	factors,	either	genetic	or	environmental,	in	the	accumulation	
of phenotypic and functionally immature NK cells.
 In conclusion, we believe that these results provide evidence for microenvironmental, 
organ-specific	 development	 and	 regulation	 of	NK	 cells,	which	 could	 clarify	 previous	findings	
that	showed	impaired	terminal	differentiation	in	peripheral	NK	cells	from	human	SLE	patients.	
Our	 data	 emphasize	 a	 larger	 role	 for	NK	 cells	 in	 SLE	 target	 organs	 than	 previously	 thought,	
and contradict the general postulation that NK cells found in PBMCs of patients can accurately 
reflect	 the	phenotypic	and/or	 functional	properties	of	NK	cells	 found	 in	 target	organs	of	SLE.	
It must also be noted, that extreme caution must be used in the interpretation of NK cell data 
coming	from	PBMCs	of	SLE	patients,	since	prednisone	and	mycophenolic	acid	are	among	the	
most	 common	 treatments	 for	 SLE,	 and	 both	 drugs	 are	 able	 to	 downmodulate	 NK	 cell	 func-
tion,	cytotoxicity,	and	proliferation	[140-143].	The	difficulties	of	being	capable	of	applying	this
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knowledge to the clinical world are obvious, even though we believe that these results indicate that 
extreme care must be taken even in clinical evaluations to disregard NK cells as non-players in 
SLE.	Indeed	our	results	show	that	NK	cells	infiltrate	the	glomeruli	of	glomerulonephritic	SLE-like	
mice, which is concomitant with an increase in localized glomerular expression of NKG2D ligands. 
Further work is needed to determine the potential of NK cells, the NKG2D receptor and its ligands 
in the development of lupus-based glomerulonephritis, to identify potential therapeutic targets.
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p85β function in murine NK cells
 The role of the p85 binding unit in DAP10 mediated signaling in NK cells has long 
been validated as being of crucial importance in NKG2D mediated cytotoxicity [83-85].  How-
ever,	 the	 specific	 role	 the	 p85β	 subunit	 plays	 in	 NKG2D	 signaling	 has	 not	 yet	 been	 estab-
lished.  By analyzing NK cell levels, and expression of developmental markers both in spleen 
and	 BM,	 we	 found	 that	 p85β	 deficiency	 does	 not	 seem	 to	 be	 correlated	 with	 any	 defects	 in	
NK	 cell	 development	 or	 maintenance.	 	 Surprisingly,	 we	 noticed	 that	 p85β	 deficiency	 caused	
NK	cells	to	exhibit	an	activated	phenotype.		Both	via	natural	(via	the	NKG2D	or	Ly49G	path-
ways) and antibody mediated activation (with NK1.1 and NKG2D), a subtle, but constant in-
crease in the cytotoxic, degranulating, and cytokine secreting capacities of NK cells was noted. 
The increase in cytokine generation is of special interest given that previous studies implicat-
ed	 the	DAP12	 via	 the	 Syk/ZAP70	 pathway	 to	 be	 responsible	 for	NKG2D	mediated	 cytokine	
production  [82, 144, 145]. This would imply a new mechanism through which the absence 
of	 the	 p85β	 subunit	 is	 capable	 of	 leaving	NK	cells	more	 prone	 to	 a	 constant	 activatory	 state.
	 This	activated	phenotype	which	we	have	noticed	in	the	p85β	deficient	mice	is	moreover	
completely	opposite	to	two	previous	reports	which	have	used	p85α	deficient	mice	[146,	147].	In	
one	study,	p85α	only	deficient	mice	showed	no	developmental	defects,	even	though	their	func-
tionality	was	not	tested	[147].		In	another	study,	the	last	five	exons	of		the	PI3KR1		gene	(which	
can	transcribe	either	for	p85α	or	the	p50α	or	the	p55α	PI3K	regulatory	subunits)	were	disrupted,	
giving	rise	to	p85α/p50α/p55α	deficient	mice	[146].		These	mice	showed	reduced	NK	cell	num-
bers both in BM and liver, and this seemed to be attributed to a reduction in the numbers of CD3-
CD122+NK1.1-CD49b- NK cell progenitors.  The remaining NK cells seemed to have reduced 
expression	of	the	Ly49	repertoire	(Ly49A,	Ly49G2,	and	Ly49D	subsets)	and	of	the	mature	NK	cell	
marker	CD43.		Furthermore,	NK	cells	from	these	to	p85α/p50α/p55α	mice	were	also	seen	to	have	
reduced	cytotoxic	capabilities	against	RMA/S	and	YAC-1	cells	and	also	had	impaired	cytokine	
production after stimulation with NK1.1 and NKG2D mAbs.  The authors of this paper discuss 
that	the	reason	for	their	deletion	of	the	p50α	and	p55α	isoforms	was	to	inhibit	any	participation	of	
these	isoforms	in	p85α	signaling.		If	the	NK	cell	phenotype	in	these	mice	is	thus	due	only	to	the	
lack	of	the	p85α	isoform,	this	would	mean	that	the	p85β	isoform	plays	a	radically	different	role	
in	the	NKG2D/DAP10	signaling	in	NK	cells.		However,	the	grave	differences	between	the	p85α	
only	deficient	mice	and	these	p85α/p50α/p55α	mice	seem	to	indicate	that	this	phenotype	might	
be	influenced	by	the	lack	of	the	p50α	and/or	p55α	subunits	in	conjunction	with	the	lack	of	p85α.
	 The	implication	of	the	p85β	subunit	in	the	internalization	of	the	NKG2D	would	imply	a	
novel role for PI3K kinases in NKG2D signaling.  The impaired internalization of the NKG2D
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receptor	could	also	explain	the	activated	phenotype	p85β	NK	cells	exhibit,	especially	after	NKG2D	
activation.  A  plausible model would be that after activation, impaired NKG2D downregulation 
would permit NK cells to signal actively via the NKG2D receptor for a prolonged period of time. 
Since	c-CBL	levels	were	seen	The	exact	mechanism	through	which	p85β	might	mediate	NKG2D	
receptor	internalization	is	yet	to	be	discovered,	however	this	deficiency	is	likely	to	contribute	to	this	
enhanced	NK	cell	activatory	status.	In	T-cells,	p85β’s	role	in	TCR	downregulation	was	mediated	via	
p85β	recruitment	of	CBL	and	c-CBL	(proteins	involved	in	T-cell	signaling	and	protein	ubiquitina-
tion),	which	participate	in	TCR	degradation	[93].	A	recent	study	has	shown	that	the	downregulation	
of	c-CBL	in	human	NK	cells	increases	NK	cell	responsiveness	and	activation	after	stimulation	via	
the	NKG2D	receptor	[148].		Thus,	seeing	how	it	is	known	how	c-CBL/p85	interactions	are	crucial	
in	TCR	downregulation,	it	might	be	interesting	to	speculate	that	this	might	be	one	of	the	possible	
mechanisms	through	which	p85β	is	involved	in	NKG2D	receptor	internalization	after	stimulation.	
 While much attention has been paid to the kinase-dependent role of the PI3K family, 
new found evidence does suggest a role for the PI3K kinases in receptor internalization, pos-
sibly as scaffold proteins [124]. The role PI3Ks play in receptor internalization have not been 
extensively	 studied,	 even	 though	 it	 has	been	noticed	 that	 some	PI3K	 isoforms,	 such	 as	p110γ	
and	p110β	play	a	 role	 in	 the	 internalization	of	either	G	protein-coupled	 receptors,	 such	as	 the	
β-adrenergic	receptors,	or	the	activated	human	platelet	derived	growth	factor	receptor	[149,	150].	
Furthermore,	two	previous	reports	have	also	noted	a	role	for	the	p85β	isoform	in	receptor	inter-
nalization,	as	p85β	deficiency	leads	to	defective	KIT	receptor	down-regulation	in	bone	marrow	
derived	mast	cells	 and	 to	defective	TCR	downregulation	 in	peripheral	CD8	T	cells	 stimulated	
with CD3 and CD28 mAbs [93, 94]. Moreover, this increase in NK cell activity would also be 
consistent	with	 a	 previous	 report	 in	which	 p85β	 deficient	T	 cells	 showed	 an	 increase	 in	 pro-
liferation	after	stimulation	with	anti-CD3	and	IL-2	[151].	In	order	 to	evaluate	 if	 this	enhanced	
activation	 has	 also	 a	 biological	 significance	 in	 vivo	we	 are	 currently	 performing	 tumor	 xeno-
graft	experiments	using	both	NKG2D	ligand	specific	and	unspecific	tumor	cells	on	p85β	mice.
	 Considering	its	role	in	inhibiting	the	correct	internalization	of	NKG2D,	p85β	might	be	in	
perspective a novel drug target for certain types of tumors which are capable of reducing surface lev-
els of NKG2D via the secretion of soluble NKG2D ligands [152].  The importance of the NKG2D 
receptor	in	tumor	clearance	has	already	been	well	documented,	and	thus	targeting	the	p85β	subunit	
might be a possible therapy in inhibiting a well-documented tumor-evasion method [153, 154].
Conclusions
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 Our studies in the possible role of NK cells in the pathogenesis of NK cells using murine 
SLE	models	demonstrate	the	following:		
1.	 The	diseased	MRL/MpJ	model	has	reduced	proportions	and	absolute	numbers	of	NK	
cells in the spleen compared to their healthy counterparts, effectively mimicking NK cell lym-
phopenia	found	in	SLE	patients	with	an	active	disease.
2.	 The	MRL	SLE-like	diseased	MRL/MpJ	and	MRL/MpJlpr show a decrease in the expres-
sion level of mature NK cell markers to a more grave extent in spleen than in bone marrow
3.	 The	MRL	SLE-like	diseased	MRL/MpJ	and	MRL/MpJlpr mice show accumulation of 
immature NK cells in the periphery but not in the BM. An increase in the number of Natural 
Killer precursor and immature CD11bLowCD27High NK cells was found in the spleen and not 
bone	marrow	of	diseased	mice.	IL-15	activated	NK	cells	from	diseased	MRL/MpJlpr	mice	show	
impaired CD107a and conjugation capacities.
4.	 The	majority	of	kidney	infiltrating	NK	are	composed	of	the	mature	CD11bHighCD27Low 
population.	Kidney	NK	cells	from	SLE-like	diseased	MRL/MpJ	and	MRL/MpJlpr mice have a 
more activated phenotype compared to healthy and predisease controls. There are more CD11b-
HighCD27Low	cells	in	diseased	kidneys,	and	these	produce	more	IFN-γ	and	phosphorylate	more	
STAT5	than	NK	cells	from	the	periphery.	The	increased	levels	of	IL-15R/IL-15	complex	in	
kidneys of diseased mice could explain the increased maturation state of NK cells in this organ. 
5.	 Rae-1	and	Mult-1	NKG2D	receptor	ligands	are	expressed	specifically	in	the	glomeruli	
of	mice	that	will	develop	SLE-like	symptoms,	and	their	expression	increases	with	worsening	
of	the	glomerulonephritic	condition.	Larger	numbers	of	infiltrating	NK	cells	are	found	in	the	
glomeruli	of	diseased	SLE-like	MRL/MpJ	and	MRL/MpJlpr mice compared to healthy controls, 
concomitantly with the increase in NKG2D ligand expression.
6.	 Constitutive	and	localized	expression	of	the	NKG2D	ligand	Rae-1	increases	the	percent	
of mature CD11bHighCD27Low	and	NK	cell	production	of	IFN-γ.
7. Preliminary results show the expression of the human NKG2D ligand MICA via immu-
nohistochemistry	in	four	out	of	six	SLE	patients	with	an	active	disease	state.
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Our	studies	using	p85β	deficient	mice	to	characterize	the	role	of	p85β	in	NK	cells	and	in	
NKG2D	signaling	demonstrate	the	following:
8.	 The	deletion	of	the	p85β	subunit	does	not	influence	NK	cell	cellularity,	differentiation,	
commitment, proliferation or conjugation. 
9.	 	The	deletion	of	the	p85β	subunit	marginally	increases	CD107a	and	cytotoxicity	after	
NKG2D	and	non-NKG2D	specific	activation	in	IL-2-activated	NK	cells.	The	deletion	of	the	
p85β	subunit	increases	cytokine	secretion	in	IL-2-activated	NK	cells	after	NKG2D	and	NK1.1	
activation 
10.	 p85β	deficient	NK	cells	internalize	less	NKG2D	after	receptor	activation,	possibly	lead-
ing to the an increased activatory state.
Conclusiones
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	 Basándonos	en	los	resultados	obtenidos	en	los	estudio	sobre	el	papel	de	las	células	NK	
en	la	patogénesis	del	lupus	utilizando	modelos	de	ratón	(MRL/MpJ	y	MRL/MpJlpr) que desarrol-
lan	una	patología	similar	al	lupus	humano	(SLE),	podemos	concluir	que:
1.		 Los	bazos	de	ratones	MRL/MpJ	que	desarrollan	lupus	presentan	una	reducción	en	el	
porcentaje	y	el	números	absoluto	de	células	NK,	comparados	con	los	bazos	de	ratones	MRL/
MpJ	sanos.	Esta	reducción	de	células	NK	es	similar	a	la	que	se	observa	en	pacientes	humanos	
con un estado activo de lupus.
2.	 	Las	células	NK	de	los	ratones	MRL/MpJ	y	MRL/MpJlpr que desarrollan lupus presentan 
una disminución en los niveles de expresión de marcadores de maduración, siendo esta dismi-
nución mayor en el bazo que en la medula ósea.
3.		 Los	ratones	MRL/MpJ	y	MRL/MpJlpr	que	desarrollan	lupus	acumulan	células	NK	
inmaduras	en		periferia	pero	no	en	la	médula	ósea:	Hay	un	aumento	del	número	total	de	precur-
sores	de	células	NK	y	de	las	células	NK	inmaduras	con	el	perfil	CD11bLowCD27High en el bazo 
pero	no	en	la	médula	ósea	de	ratones	enfermos.	Las	células	NK	obtenidas	de	ratones	MRL/
MpJlpr	enfermos	y	activadas	con	IL-15	muestran	defectos	en	la	degranulación	(de	la	proteína	
CD107a)	y	en	la	capacidad	de	conjugarse	con	células	dianas.
4.		 La	mayor	parte	de	las	células	NK	que	infiltran	los	riñones	de	ratones	sanos	y	enfermos	
presentan un fenotipo de población madura CD11bHighCD27Low.	Las	células	NK	que	infiltran	los	
riñones	de	ratones	MRL/MpJ	y	MRL/MpJlpr	que	desarrollan	lupus	muestran	un	fenotipo	más	
activado	que	el	de	las	células	NK	que	infiltran	los	riñones	de	ratones	sanos	control:	Hay	más	cé-
lulas NK maduras CD11bHighCD27Low	en	los	riñones	de	ratones	enfermos,	y	éstas	producen	más	
IFN-γ	y	presentan	mayores	niveles	de	fosforilación	de	STAT5	que	las	células	NK	en	la	periferia.	
Los	mayores	niveles	del	complejo	IL-15/IL-15R	detectados	en	los	riñones	de	ratones	enfermos	
podrían	explicar	el	aumento	del	número		células	NK	maduras	infiltradas.
5.		 Los	ligandos	del	receptor	NKG2D,	Rae-1	y	Mult-1,		se	expresan	de	forma	específica	en	
los	glomérulos	de	los	ratones	que	desarrollan	lupus.	La	expresión	de	estos	ligandos	aumenta	con	
la	progresión	de	la	patología	glomerulonefrítica.	En	los	glomérulos	de	los	ratones	enfermos	hay	
más	infiltración	de	células	NK	que	en	los	glomérulos		de	ratones	control,	lo	que	correlaciona	con	
el aumento de la expresión de los ligandos NKG2D.
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6.		 La	expresión	constitutiva	y	localizada	del	ligando	de	NKG2D	Rae-1e en modelos de 
ratón aumenta el porcentaje de la población NK madura CD11bHighCD27Low y la producción de 
IFN-γ	por	parte	de	células	NK.
7.		 Resultados	preliminares	demuestran	la	expresión	del	ligando	de	NKG2D	MICA	en	cu-
atro	de	seis	pacientes	con	SLE	con	un	estado	activo	de	la	enfermedad.	
Los	resultados	obtenidos	utilizando	ratones	deficientes	en	p85β	para	caracterizar	el	papel	de	
la	subunidad	p85β	de	PI3K	en	el	desarrollo	y	función	de	las	células	NK,	así	como	en	la	señal-
ización	vía	NKG2D	nos	permiten	concluir	que:
8.		 La	ausencia	de	la	subunidad	p85β	no	influye	en	el	numero,	diferenciación,	proliferación,	
o	conjugación	de	células	NK.
9.	 	La	ausencia	de	la	subunidad	p85β	aumenta	de	forma	marginal	la	degranulación	(de	la	
proteína	CD107a)	y	la	citotoxicidad	de	células	NK	cultivadas	con	IL-2	cuando	éstas	entran	en	
contacto	con	células	diana	que	expresan	ligandos	de	NKG2D	o	de	Ly49G2.	La	ausencia	de	la	
subunidad	p85β	permite	una	mayor		secreción	de	citoquinas	en	células	NK	cultivadas	con	IL-2	
cuando	se	activan	a	través	de	los	receptores		NKG2D	y/o	NK1.1.
10.	 	Células	NK	deficientes	en	p85β	internalizan	menos	receptor	NKG2D	tras	su	activación,	
lo	que	posiblemente	conduce	a	un	estado	de	activación	mas	agudo	en	estas	células	NK.
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